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Die pränatale Expression der mRNA und des Protein vom Prion-Proteingen PRNP  
beim Schaf 
 
Die Expression des Prion-Protein (PRNP) Gens wurde auf den Ebenen mRNA und 
Protein in den Geschlechtsorganen des weiblichen Schafs sowie verschiedenen 
Geweben von Schafsföten unterschiedlicher Trächtigkeitsstadien untersucht. 
Reproduktive Organe wie Ovar, Eileiter, Endometrium, Myometrium und Karunkel 
wurden während dem ersten, dritten und fünften Trächtigkeitsmonat beprobt. Im ersten 
Monat der Entwicklung wurde der gesamte Fötus beprobt, beim zweimonatigen Fötus 
wurden Proben von Gehirn, Kotyledonen, Herz, Darm, Niere, Leber, Lunge und Muskel 
entnommen. Bei den drei und fünf Monate alten Föten wurden zusätzlich Proben von 
Rückenmark und Gehirn entnommen. Die Schafe wurden anhand ihrer PRNP 
Genotypen in die Kategorien resistent gegen (R1) oder anfällig für (R5) Scrapie 
eingestuft. In beiden Genotypgruppen konnten die Gentranskripte in allen Stadien und 
allen untersuchten Geweben mit einer RT-PCR nachgewiesen werden. Das Profil der 
Genexpression der R1 und R5 Gruppen war ähnlich. Der Vergleich der reproduktiven 
Organe zeigte das höchste Expressionslevel im Karunkelgewebe der Mutterschafe, 
während das Level im Gehirn hoch und in der Leber der Feten niedrig war. Zusätzlich 
wurde eine Real-Time RT-PCR in unreifen Oozyten, reifen Oozyten, in vivo 
Embryonen zum Morulastadium und in einmonatigen Föten durchgeführt. Die 
Ergebnisse zeigten, dass das relative Expressionslevel der PRNP mRNA in reifen 
Oozyten und Embryonen im Morulastadium signifikant niedriger war als in unreifen 
Oozyten und einmonatigen Föten (p≤0,05). Fluoreszenz in situ Hybridisierung von 
adulten Ovarien und einmonatigen Föten wies die Gentranskripte in Oozyten, 
Granulosazellen, Thekazellen, Ovarrinde, Ovarmark und Gelbkörpern der Ovarien und 
im Gehirn, Wirbelsäule, Dermatom, Herz, Leber und Niere der Feten beider Gruppen 
nach. Eine Westernblot-Analyse zeigte die zu PrPC korrespondierenden immunreaktiven 
Banden in allen weiblichen Reproduktionsgeweben ebenso wie in den einmonatigen 
Föten. Das PrPC wurde ebenfalls in allen Geweben des zweimonatigen Fötus gefunden. 
Zusätzlich implizierte die immunohistochemische Färbung die Lokalisation des PrPC in 
Gehirn, Herz und Niere des einmonatigen Fötus. Das PrPC wurde in dieser 
Untersuchung ebenfalls in beiden Gruppen in der Rinde und im Mark des Ovars jedoch 
nicht in Oozyten, Granulosazellen, Thekazellen und Gelbkörpern nachgewiesen. 
The prenatal expression of mRNA and protein of the prion protein gene, PRNP,  
in sheep 
 
The expression of the prion protein gene both on mRNA and protein levels were 
investigated in ovine female reproductive organs and in various tissues of their foetuses 
during the prenatal stage. Reproductive organs such as ovary, oviduct, endometrium, 
myometrium and caruncle were collected at the 1st, 3rd and 5th month of pregnancy. 
Foetal tissues were the whole foetuses at 1 month of age, brain, cotyledon, heart, 
intestine, kidney, liver, lung and muscle of 2-month-old foetuses. At 3 and 5 months of 
age the spinal cord and spleen were added. Sheep were categorized as resistant (R1) or 
high susceptible (R5) to scrapie according to their PRNP genotype. In both genotype 
groups, the gene transcript was detectable in all stages and all tissues examined by RT-
PCR. The gene expression profiles of R1 and R5 groups were similar. Comparisons 
between reproductive organs demonstrated the highest expression level in caruncle 
tissue of ewes, whereas the level was high in brain and low in liver of their foetuses. In 
addition, real-time RT-PCR was performed in immature oocytes, mature oocytes, in 
vivo embryos at morula stage and in 1-month-old foetuses. The results showed that the 
relative expression levels of PRNP mRNA in mature oocytes and morula-stage embryos 
were significantly lower than those in immature oocytes and 1-month-old foetuses 
(p≤0.05). Fluorescent in situ hybridisation in adult ovaries and 1-month-old foetuses 
demonstrated the presence of the gene transcript in oocytes, granulosa cells, theca cells, 
ovarian cortex, ovarian medulla and corpus lutuem of the ovaries, and in brain, vertebral 
column, dermatome, heart, liver and kidney of the foetuses of both groups. Western blot 
analyses revealed the immunoreactive bands corresponding to PrPC in all female 
reproductive tissues as well as their foetuses collected at the 1st month gestation. The 
PrPC was also detected in all tissues of 2-month-old foetuses. In addition, 
immunohistochemical staining implicated localisation of PrPC in brain, heart and kidney 
of 1-month-old foetuses. The PrPC was also found in ovarian cortex and ovarian 
medulla of the two groups however, it was undetectable in oocytes, granulosa cells, 
theca cells and corpus luteum, in this study. 
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1 Introduction  
 
Transmissible spongiform encephalopathies (TSEs) are fatal neurodegenerative 
disorders of the central nervous system (CNS) caused by prions. Prion diseases include 
bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep and goats, 
Creutzfeldt Jakob Disease, Gerstmann Sträussler syndrome, fatal familial insomnia, 
Kuru and Alpers syndrome in humans. The primary cause of these diseases is a post-
translational conformation change in a host-encoded cellular prion protein (PrPC) to  
a proteinase-resistant form (PrPSc) (Prusiner 1991). Various studies showed that mice 
devoid of functional PRNP gene are resistant to scrapie and do not allow propagation of 
the infectious agent (Brandner et al. 1996, Bueler et al. 1993, Sailer et al. 1994, 
Sakaguchi et al. 1996, 1995). Moreover, it has been suggested that the absence of PrPC 
expression is not the cause of neuronal dysfunction, animals devoid of PrPC are not 
damaged by exogenous PrPSc, and the amount of PrPC is a rate-limiting step in the 
development of the prion disease (DeArmond and Prusiner 1996).  
PRNP has been shown to be expressed at high levels in CNS but also in many non-
neuronal tissues such as heart, skeletal muscle, lung, intestinal tract, spleen, testis, 
ovary, lymphocytes, lymph nodes and some other organs in rodents and ruminants 
(Bendheim et al. 1992, Mabbott et al. 1997, McBride et al. 1992, Pammer et al. 1998). 
PrPC is a normal protein located on the exterior cell surface and is attached to the 
plasma membrane via a glycosylphosphatidylinositol (GPI) anchor (Stahl et al. 1990). 
This protein is believed to be involved in several functions in the cell such as protection 
against antioxidant activity by regulating copper ion concentration (Brown et al. 2001, 
2002, Klamt et al. 2001) transduction of neuroprotective signals or even prevention of 
apoptosis in retinal cells (Chiarini et al. 2002). Although, it’s precise function(s) 
remains unclear.  
Susceptibility to scrapie in sheep is influenced by polymorphisms at codons 136, 154 
and 171 of the PRNP gene (Tranulis 2002). The ovine PRNP genotypes were classified 
into 5 risk groups according to the susceptibility to the disease; R1 genotype being the 
resistant and R5 genotypes being high susceptible to the disease (Erhardt et al. 2002). 
Tuo et al. (2002) reported that accumulation of PrPSc in uterine-placental epithelial cells 
in the placentome was influenced by the foetal PRNP genotype and the pregnancy status 
of scrapie-infected ewes.  
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In natural TSE infections the gastrointestinal tract is considered to be the major route of 
the infection (Andreoletti et al. 2000, Hadlow et al. 1982, Pattison et al. 1972), and the 
scrapie infectious prions diffused to sheep and goat are hypothesized to originate from 
placenta of infected ewes (Andreoletti et al. 2000, Pattison et al. 1972, Tuo et al. 2001). 
Oral and parental inoculation of PrPSc resulted in 100% infection of the prion disease in 
mice (Manolakou et al. 2001, Narang 1996, Narang 2001). Epidemiology shows that 
maternal vertical transmission of TSE is not of importance; however, embryo transfer 
experiments performed in sheep provide contradictory results about the possibility of 
this mode of infection including those providing support for maternal vertical infection 
(Foster et al. 1996) or those showing prevention of vertical infection by embryo transfer 
(Foote et al. 1993, Wang et al. 2002, 2001).  
Since the expression of PRNP is a prerequisite for the infection, studies on the temporo-
spatial expression of PRNP in foetal and maternal tissue during gestation can provide 
further clues on the impact of maternal vertical transmission of TSE. Moreover, these 
expression profiles contribute to the elucidation of the physiological function of the 
protein. Therefore, the aims of this study were: 
1) Quantitative expression profiling of the PRNP gene in R1 and R5 ovine immature 
oocytes, mature oocytes and in vivo preimplantation embryos using real-time PCR. 
2) Semi-quantitative expression profiling of the PRNP gene during prenatal stages in R1 
and R5 ovine foetal and maternal tissues using RT-PCR technology. 
3) Detection of PrPC in R1 and R5 female reproductive tissues of ewes and whole 
foetuses at the 1st month of pregnancy as well as various tissues of 2-month-old foetuses 
by western blot.  
4) Detection and localisation of PRNP mRNA and PrPC in adult ovaries and 1-month-
old foetuses of both groups. 
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2 Literature review 
 
2.1 Prion diseases 
 
Prion diseases or transmissible spongiform encephalopathies (TSEs) are fatal 
neurodegenerative disorders of the central nervous system that occur in a number of 
species. The clinical signs of these diseases are variable but include progressive 
dementia, cerebellar ataxia and behavioural disturbances. Gross neuropathology can 
include reduced brain weight, cortical atrophy and enlargement of the ventricles 
(reviewed in Moore and Melton 1997). Histophatological changes of the brain comprise 
a fine vacuolation termed spongiosis, reactive changes of astrocytes called gliosis, and 
variable loss of neurons (reviewed in Brandner et al. 2000). Widespread apoptosis has 
been described in the brain of infected sheep, mice and human and may be a major 
mode of cell death (Fraser 1976). 
Prion diseases are found in both animals and human including bovine spongiform 
encephalopathy (BSE) or mad cow disease in cattle, chronic wasting disease (CWD) in 
elk and deer, transmissible mink encephalopathy (TME) in mink, feline spongiform 
encephalopathy (FSE) in cat, puma, cheetah, ocelot and tiger, and ovine spongiform 
encephalopathy (OSE) or scrapie in sheep and goat. The prion diseases in human are 
Alpers syndrome, Kuru, fatal familial insomnia (FFI), Gerstmann–Sträussler–Scheinker 
syndrome (GSS), Creutzfeldt–Jakob disease (CJD) and a new variety of Creutzfeldt–
Jakob disease (nv CJD) which is caused by the transmission of BSE via dietary 
exposure (Moore and Melton 1997, Will et al. 1996) (Table 1). The possibility that the 
infectious agent of prion disease consists of viral particles can be ruled out, since no 
nucleic acid has been detected. The protein-only hypothesis has been formulated firstly 
by Griffith (1967), and supported by additional data of Prusiner (1982) who coined the 
term prions, composed from “proteinaceous infectious particle” to identify the agents 
that cause a novel type of fatal brain diseases. The hypothesis states that the infectious 
prion protein is devoid of nucleic acid, and the primary cause of these diseases is a post-
translational conformation change in a host-encoded cellular prion protein (PrPC) to the 
disease-causing isoform (PrPSc) (Prusiner 1991, 2004). 
 Table 1: Transmissible spongiform encephalopathies (Adapted from Moore and Melton 1997, Prusiner 1994, 2004) 
 
Species Disease Description Distribution 
Sheep Scrapie Field scrapie; infection in genetically susceptible sheep. Experimentally transmitted 
to sheep, goats, mice, hamsters and cattle (Gibbs et al. 1990, Okamoto et al. 2003). 
Worldwide 
(1936) 
Goat Scrapie Natural cases rare  
Mink Transmissible mink 
encephalopathy 
Infection in farmed mink; source of infection probably scrapie infected offal. 
Experimentally transmitted to hamsters. 
North America; 
Europe 
Mule 
Deer 
Chronic wasting 
disease 
Infection of farmed deer probably from scrapie contaminated feed.  
Experimentally transmitted to other deer. 
North America 
Elk Chronic wasting 
disease 
Infection in farmed elk, probably derived from scrapie infected feed.  
Cattle Bovine spongiform 
encephalopathy 
UK BSE epidemic mostly in Holstein Friesian dairy cattle; scrapie contamination of 
feed. Experimentally transmitted to mice (Fraser et al. 1992), pigs (Ryder et al. 
2000), monkeys (Lasmezas et al. 2005, 1996) and mink (Robinson et al. 1994). 
UK; Republic 
of Ireland; 
Europe 
Domestic 
cat 
 Infection with prion-contaminated bovine tissues or MBM in domestic cats. 
Transmitted to mice (Fraser et al. 1994) 
UK; Norway 
Cheetah  Infection in a zoo specimen UK 
Puma  Infection in a zoo specimen UK 
MBM: meat and bone meal
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 Table 1: Transmissible spongiform encephalopathies (Continued, adapted from Moore and Melton 1997, and Prusiner 1994, 2004) 
 
Species Disease Description Distribution 
Human Sporadic CJD Sporadic: 1:106 incidence; not associated with prion protein (PrP) mutations. 
Experimentally transmitted to chimpanzees, monkeys, cats and mice 
Worldwide 
 Iatrogenic CJD Iatrogenic: transmission following neurosurgery, corneal transplant and dura mater graft Worldwide 
 Familial CJD Familial: linked to mutations in prion protein; autosomal dominant, some have variable 
penetrance 
Worldwide 
 New variant CJD Unusual CJD variant in UK (10 cases) and France (1 case) with early onset  
(<42 years), unusual clinical presentation and neuropathology.  
Infection from bovine prions. Transmissibility to rodents not yet demonstrated. 
UK; France 
 Gerstmann-
Scheinker- 
Sträussler Syndrom 
Familial disorder tightly linked to mutations in the prion protein Worldwide 
 Fatal familial  
insomia 
Familial disorder linked to germline mutation in prion protein in association with a 
common PrP polymorphism 
Worldwide 
 Kuru Infection: Sporadic CJD spread and maintained by cannibalism; endemic to a remote 
highland region of Papua New Guinea. Experimentally transmitted to goats, primates and 
rodents 
Papua New 
Guinea 
(1950) 
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2.2 Incubation time and transmission of prion diseases 
 
When the titre of infectious prion reaches a critical threshold, animals develop signs of 
neurologic dysfunction. The time interval from inoculation to clear signs of the disease 
is referred to as the incubation period. The length of incubation period can be modified 
by the dose of the infectious agent, the route of inoculation, the level of PrPC and 
polymorphism in the sequence of PrPC (Prusiner et al. 2004). Since the mean incubation 
time for BSE is ~4-5 years, most cattle do not manifest the disease because they are 
slaughtered between 2-3 years of age (Spongiform Encephalopathy Advisory 
Committee 1995). For the scrapie in sheep, the incubation period range from 3.5 – 23 
months after intracerebral injection with a source of scrapie known as SSBP/1 
(Dickinson 1976).  
 
2.2.1 Transmission of human prion diseases 
 
The infection route of Kuru is composed of a combination of consumption, ocular 
exposure and skin exposure to the infected, uncooked and cooked tissues of dead 
patients at mortuary rituals of the Fore people in Papua New Guinea (Spongiform 
Encephalopathy Advisory Committee 1995). For the CJD, it seems unlikely that the 
disease is spread among humans by infection except in the cases of accidental 
inoculations. Most of CJD cases are sporadic and are the result of a somatic mutation, 
the spontaneous conversion of PrPC to PrPSc, or reduced clearance of low levels of PrPSc 
that are normally present (Prusiner et al. 2004). 
 
2.2.2 Transmission of BSE and scrapie 
  
BSE in cattle appears to be transmitted through concentrate feeds containing ruminant-
derived meat and bone meal (MBM). The MBM is prepared from the offal of sheep, 
cattle, pigs and chicken as a high-protein nutritional supplement. The hydrocarbon-
solvent extraction method is used in the rendering of offal results in MBM with much 
higher fat content. This process allowed scrapie prions from sheep to survive rendering 
and subsequently to be passed into cattle (Prusiner et al. 2004, Spongiform 
Encephalopathy Advisory Committee 1995). However, an ability of the bovine 
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gastrointestinal microbiota to degrade the infectious prions during digestion was 
observed. Scherbel et al. (2006) demonstrated that after incubation of the microbial 
consortia collected from rumen and colon with brain homogenates of scrapie infected 
hamsters for 20 hours, PrPSc was digested up to immunochemically undetectable levels. 
Especially polymyxin resistant (mainly gram-positive) bacteria expressed PrPSc 
degrading activity.  
In sheep and goat, the natural route by which infectious agents are transmitted among 
these species is unknown. However, in natural scrapie, the gastrointestinal tract is 
considered to be the major route of infection (Hadlow et al. 1982). Some investigations 
have suggested that horizontal transmission occurs orally, and the scrapie infectious 
prions diffused to sheep and goat are hypothesized to originate from placenta of infected 
ewes (Andreoletti et al. 2000, Pattison et al. 1972, Tuo et al. 2001). Nevertheless, there 
is no evidence for vertical transmission or for transmission through semen and embryos 
(Wrathall 1997).  
For experimentally transmission, scrapie and BSE can be transmitted through multiple 
routes (Wrathall 1997). The disease was first transmitted by intraocular inoculation 
(Cuille and Chelle 1939, reviewed in Prusiner 2004) and later by intracerebral 
(Dickinson 1976, Renwick and Zlotnik 1965), oral (Prusiner et al. 1985), subcutaneous 
(Buyukmihci et al. 1985), intravenous (Kimberlin and Walker 1989) and intragastrical, 
intracardiac and intramuscular (Zhang et al. 2004) injections. However, many of the 
inoculated animals often failed to develop the disease (Dickinson and Stamp 1969, 
Hadlow et al. 1980, 1982). Moreover, many studies showed that different PRNP 
genotypes of sheep influenced the incubation time and susceptibility to scrapie prions 
inoculated, suggesting that the genetic background influence host permissiveness 
(Bulgin et al. 2006, Goldmann et al. 1991a, Maciulis et al. 1992, O'Rourke et al. 1997). 
  
2.2.3 Maternal –vertical transmission 
 
Epidemiology shows that maternal vertical transmission of TSE is not of importance; 
however, embryo transfer experiments performed in sheep provide contradictory results 
about the possibility of this mode of infection including those providing support for 
maternal vertical infection (Foster et al. 1996) or those showing prevention of vertical 
infection by embryo transfer (Foote et al. 1993, Wang et al. 2002, 2001).  
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Foster et al. (1996) examined the effect of washing the embryos and the viability of 
highly susceptible offspring derived from scrapie-affected and uninfected donors. The 
results showed that scrapie occurred in both washed and unwashed embryos from both 
groups of donor ewes. This is in contrast to the study of Foote et al. (1993), who 
measured scrapie transmission via the embryo by using offspring from embryos of 
scrapie-inoculated donors and scrapie-free recipients, and via the uterus by using 
offspring from embryos of scrapie-free donors and scrapie-inoculated recipients taken 
by cesarean section. The results showed that none of the scrapie-free donor/recipients, 
including those gestating embryos from scrapie-inoculated donors, and the offspring 
from reciprocal cross, via embryo, or via the uterus developed scrapie. These 
investigations were supported by the studies in cattle (Wrathall et al. 2002) and sheep 
(Wang et al. 2002, 2001). The results reported that embryos collected from donors with 
a high incidence of clinical or natural prion disease did not develop the diseases even 
many embryos had the high risk genotype. In a study of experimental BSE of Foster  
et al. (2004), Cheviot ewes challenged orally with BSE cattle brain produced lambs of 
various PRNP genotypes. Of 72 surviving to >30 months of age, 29 are of the most 
susceptible PRNP genotype (A136Q171/A136Q171, the underscript numbers present the 
order of amino acid) and born to mothers that were challenged with BSE. However, 
none of the progeny have shown any signs of BSE disease. From these studies it could 
be concluded that prion diseases were not neither transmitted to offspring via the 
embryo nor was the infective agent transmitted to recipient animals during embryo 
transfer procedures even when the offspring have the high risk genotype. In addition, 
since PrPSc was detected in placenta from scrapie-infected ewes (Race et al. 1998) and 
oral inoculation is a major route of scrapie infection, by which lambs may be exposed to 
scrapie by ingesting the transmissible agent during contact with contaminated wool and 
mammary gland of the dam (Tuo et al. 2001). 
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2.3 Prion protein 
 
2.3.1 Structure of prion protein 
 
The mammalian PRNP encodes a protein of ~250 amino acids (aa) that contains several 
distinct domains, including an amino-terminal signal peptide, a series of five peptide 
repeats, a central hydrophobic segment and a carboxy-terminal hydrophobic region that 
is a signal for addition of a glycosyl phosphatidyl inositol (GPI) anchor (Harris et al. 
2004). The amino acid sequences of prion protein (PrP) in human, cattle, sheep and 
mouse with long and short incubation period for prion disease are shown in Figure 1 
and Figure 2. Codon and amino acid abbreviations are shown in appendix 1.  
The human prion protein contains 253 aa (AAG21693) while cattle and sheep prion 
proteins contain 264 (CAA39368) and 256 (CAA04236) aa, respectively. Mouse PrP 
with long and short incubation time have the same number of 254 aa (AAD41440 and 
AAC02804, respectively). The amino acid sequences of prion protein in these four 
species are quite similar especially when comparing between human and mouse (Figure 
2), and cattle and sheep (Figure 1). Differences in the sequence of prion protein in 
mouse with long and short incubation time are a substitution of leucine (L) to 
phenylalanine (F) at codon 109, and threonine (T) to valine (V) at codon 190. Between 
human and mouse, the differentiation in prion protein sequences consist of  26 aa was 
observed, in which a deletion at codon 56, and an insertion of two amino acids between 
codons 226 and 227 in mouse PrP sequence (residual number refer to the number of 
human PrP). Comparison between bovine and ovine prion protein sequences shows an 
insertion of eight amino acids in bovine PrP at codons 92-99, and substitution of serine 
(S) -> threonine (T), serine (S) -> glycine (G), asparagine (N) -> serine (S), tyrosine (Y) 
-> histidine (H), and isoleucine (I) -> methionine (M) at codons 106, 108, 154, 166 and 
216, respectively (residual number refer to the number of bovine PrP). 
The characteristic secondary structure elements of prion protein are three alpha helices, 
with two small beta-sheets. From the human PrP structure shown in Figure 3A, three 
helices are shown as HA, HB and HC while two beta-sheets are shown as S1 and S2, 
and two N-linked polysaccharides are shown at top left and center. HA is a short helix, 
spanning residues 144-154, HB is a regular helix spanning 173-194, and HC is longer. 
The two glycosylation sites are asparagine 181 on the HB, and asparagine 197 between 
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HB and HC (human sequence). One disulfide bond is present in the protein connecting 
the second and third helices via cysteine179-cysteine 214 (Govaerts et al. 2004). 
 
 
(A)   (B) 
 
.  
 
Figure 3: Model of the C-terminus of human prion protein (A). Structure model of 
PrPC and PrPSc (B) 
 
 
2.3.2 Biochemical and biophysical differences between PrPC and PrPSc 
 
PrPC is a normal cellular host-encoded glycoprotein found in neuron system of 
mammals. It is located on the exterior cell surface and is attached to the plasma 
membrane via a GPI anchor (Stahl et al. 1990). PrPSc is a modified isoform of PrPC 
originated by a conformation change of PrPC during a posttranslational process. This 
modification is non genomic protein and causes TSEs in humans and animals (Prusiner 
1982).  
Since both of PrPC and PrPSc have the same primary amino acid sequence and similar 
N-linked carbohydrate side chain and GPI anchors, chemical differences between PrPC 
and PrPSc are not found (Stahl et al. 1993). However, biochemical and biophysical 
differences between PrPC and PrPSc have been identified. PrPC is a non-infectious agent, 
soluble in soft detergent and sensitive to proteinase K digestion. In contrast, PrPSc is an 
infectious agent associated with prion diseases infectivity, insoluble in soft detergents 
and resistant against digestion of proteinase K. Moreover, infrared spectroscopy 
PrPc PrPsc
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indicated that the secondary structure of PrPC contains approximately 42% alpha-helix 
and 3% beta-sheet, whereas PrPSc contains 30% alpha-helix and 43% beta-sheet (Figure 
3B, Pan et al. 1993). In addition, while a tertiary structure of PrPC included a long 
flexible N-terminal tail, three alpha-helix and two small anti-parallel  
ß-strands that flank the first alpha-helix, a tertiary structure of PrPSc has not yet been 
obtained (Harris 1999). 
 
2.3.3 Conversion of PrPC into PrPSc 
 
The mechanism of the conversion of PrPC to PrPSc is not well understood. However, 
cell-free conversion studies indicate that PrPSc aggregates are able to convert PrPC into  
a protease-resistant PrP isoform (Bessen et al. 1995, Kocisko et al. 1996). In order to 
explain the mechanism by which an infectious form of PrP could induce the refolding of 
native PrP molecules into the abnormal conformation, three distinct models have been 
postulated: (i) the template-directed model (ii) the template-assisted model and (iii) the 
nucleation-polymerisation model (Figure 4). The first and second models postulate an 
interaction between exogenously introduced PrPSc and endogenous PrPC, and  
a prevention of spontaneous conversion of PrPC and PrPSc by high energy barrier. The 
first model (Figure 4A) suggests that PrPSc forms a heterodimer with PrPC and causes 
PrPC to undergo an induced conformational change to yield PrPSc (Prusiner 1991). The 
template-assisted model (Figure 4B) states that in an uninfected cell, PrPC with wild 
type sequence is likely to exist in equilibrium with its monomeric alpha-helical, 
protease-sensitive state or bound to some other proteins, such as protein X. The 
conformation of PrPC that is bound to protein X is denoted PrP*. This PrP*-protein X 
complex will bind PrPSc, thereby creating a replication-competent assembly. When PrP* 
is transformed into a nascent molecule of PrPSc, protein X is released and a dimer of 
PrPSc remains. In this model, a fraction of infectious PrPSc dimers dissociates into 
uninfectious monomers as the replication cycle proceed, while a majority of the dimers 
accumulate in accord with the increase in prion titer that occurs during the incubation 
period (Prusiner 2004). The nucleation model (Figure 4C) proposes that PrPC and PrPSc 
are in equilibrium, strongly favouring PrPC. The PrPSc is only stabilized when it adds 
onto a crystal-like seed or aggregate of PrPSc. If a stable aggregate needs to consist 
minimally of a substantial number of PrPSc molecules, then its spontaneous formation 
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would be a very rare event. However, once a seed is present, monomer addition could 
ensue at a rapid rate. Fragmentation of PrPSc increases the number of nuclei which can 
recruit further PrPSc and results in apparent replication of the agent (reviewed in 
Weissmann 1999). 
 
 
 
 
 
 
 
 
Figure 4: Hypothetical scheme for the conformational conversion of PrPC into 
PrPSc. The template-directed model (A), the template-assistance model (B) and the 
nucleation-polymerisation model (C) 
 
Literature review                                                                                                                                          14 
 
2.3.4 Function of PrPC 
 
The precise function(s) of PrPC remains unclear, but the localisation of PrPC on the cell 
surface would be consistent with roles in cell adhesion and recognition, ligand uptake, 
or transmembrane signalling. Defining the physiological role of PrPC may be relevant to 
understanding the disease state, since the protein may fail to perform its normal function 
when it is converted to the PrPSc isoform (Harris 1999). It has been shown that mice 
homozygous for disrupted PRNP (PRNP-/-) developed and behaved normally for at least 
7 months, and no immunological defects were apparent (Bueler et al. 1992). On the 
other hand, some studies presented that PRNP-/- mice revealed an alteration in circadian 
activity rhythms and sleep patterns (Tobler et al. 1997, 1996), abnormalities of synaptic 
neurophysiology in the hippocampus (Colling et al. 1996, Whittington et al. 1995), loss 
of Purkinje cells in the vast majority of cerebellar folia (Sakaguchi et al. 1996) and  
a disturbance in latent learning and long-term memory retention (Nishida et al. 1997). 
However, other investigators did not observe certain of these features (Herms et al. 
1995, Lledo et al. 1996) 
PrPC has been suggested to be involved in several functions in the cell, such as copper 
metabolism, since PRNP-null mice display a reduction in the copper content of 
membrane-enriched brain extracts and synaptosomal fractions, and a reduced activity of 
copper/zinc superoxide dismutase (Brown et al. 1997). Additional possible functions of 
the PrPC are protection against oxidative stress by regulating copper ion concentration 
(Brown et al. 2001, 2002, Klamt et al. 2001), transduction of neuroprotective signals 
and prevention of apoptosis function in retinal cells (Chiarini et al. 2002). An additional 
study on antiapoptotic function of PrPC was done by Liang et al. (2006), who introduced 
either the PrPC or two pairs of RNAi into the gastric cancer cell line. The results showed 
that PrPC slowed down apoptosis in transfected cells. In addition, the apoptosis-related 
protein Bcl-2 was upregulated, whereas Bax was downregulated in the PrPC-transfected 
cells. These contrast the results in RNAi-transfected cells that showed the 
downregulated Bcl-2 and upregulated Bax. These results suggested that PrPC might play 
a role as an effective antiapoptotic protein through Bcl-2-dependent apoptotic pathways 
in gastric cancer cells. 
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2.3.5 Role of PrPC in prion diseases 
 
According to the protein only hypothesis, PrPC is a substrate for the infection of prion 
diseases to start by the conversion of PrPC into PrPSc. An important corollary to this 
hypothesis is that an organism lacking PrPC should be resistant to prion disease and 
unable to propagate the infectious agent. To this end, many groups generated mice with 
a targeted disruption of the PRNP gene. The results showed that after challenged with 
infectious prions, PRNP knockout mice were completely protected against scrapie 
disease and did not allow propagation of the infectious agent (Bueler et al. 1993, Sailer 
et al. 1994, Sakaguchi et al. 1996, 1995). Moreover, after grafting neural tissue with 
PRNP over expression into the brain of PRNP-deficient mice followed by intracerebral 
inoculation with scrapie prions, the grafts accumulated high levels of PrPSc and 
infectivity, and developed the severe histopathological changes characteristic of scrapie, 
whereas no pathological changes were seen in PRNP-deficient tissue, not even in the 
immediate vicinity of the grafts (Brander et al. 1996). In addition, heterozygous mice 
with only one disrupted allele (PRNP+/0) showed partial resistance to scrapie infection 
as manifested by prolonged incubation times of ~290 days compared to ~160 days in 
Prnp+/+ mice (Bueler et al. 1994). It has been showed that when a Syrian hamster (SHa) 
PrP transgene was introduced into PRNP0/0 mice by crossing them with transgenic 
(SHaPrP) mice, the transgenic (SHaPrP) mice became susceptible to SHa prions but not 
to mouse prions (DeArmond and Prusiner 1996). These suggest that the absence of PrPC 
expression is not the cause of neuronal dysfunction, animals devoid of PrPC are not 
damaged by exogenous PrPSc, and the amount of PrPC is a rate-limiting step in the 
development of the prion disease.  
 
2.3.6 Expression of PrPC 
 
PrPC has been observed at high level in central nervous system (CNS) and could be 
detected in several non-neuronal tissues such as squamous epithelia of the skin and 
upper gastrointestinal tract of human (Pammer et al. 1998), leukocytes, heart, skeletal 
muscle, lung, intestinal tract, spleen, testis, ovary, lymph nodes, Peyer's patches, 
thymus, and pancreas of mice and cows (Bendheim et al. 1992, McBride et al. 1992), as 
well as on the surface of lymphocytes in humans and mice (Mabbott et al. 1997).  
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A prion protein isoform truncated at the C terminus has been detected in ram (Ecroyd et 
al. 2004), human and cattle mature sperm cells (Shaked et al. 1999), which retain only 
the minimal components required for their unique function. Horiuchi et al. (1995) 
demonstrated the distribution of PrPC in sheep organs and showed that PrPC can be 
detected in several tissues besides the brain such as spleen, lymph node, lung, heart, 
kidney, skeletal muscle, uterus, adrenal gland, parotid gland, intestine, proventriculus, 
abomasum and mammary gland. 
In brain, immunohistochemical studies have described a somatic expression of PrPC in 
neurons with no or only a minor signal in the neuropil, which is a network of 
unmyelinated neuronal processes (axonal and dendritic) within the gray matter of the 
CNS. By electron microscopy, PrPC labelling in the neuropil was found on the plasma 
membrane of dendrites, including spines, as well as dendritic transport vesicles, 
endosomes, axolemma, axonal transport vesicles and myelin sheaths. In both neuronal 
and glial cells, PrPC was detected in the endoplasmic reticulum, Golgi complex, 
endosomes, uncoated transport vesicles and the plasma membrane, which are important 
parts of the biosynthetic and endocytic pathway (reviewed in Harris et al. 2004). 
 
2.3.7 Accumulation of PrPSc 
 
In natural scrapie, the gastrointestinal tract is believed to be the major route of infection. 
The earliest accumulations of PrPSc are found in ileal Peyer’s patch, tonsil, 
retropharyngeal lymph nodes, mesenteric-portal lymph nodes, and intestine. 
Accumulation of PrPSc in the enteric nervous tissue has been reported to appear later but 
still in an early phase of the disease (Andreoletti et al. 2000, Hadlow et al. 1982, 
Maignien et al. 1999). PrPSc also aggregates in other tissues such as tingible body 
macrophages (TBMs), follicular dendritic cells (FDCs), distal jejunal lymph node, 
medial retropharyngeal lymph node (RPLN), spleen and placenta in sheep with both 
clinical and nonclinical disease (Ersdal et al. 2003, Jeffrey et al. 2000, Race et al. 1998, 
Schreuder et al. 1998, van Keulen et al. 1996). The earliest traces of PrPSc in the brain 
have been found in the autonomic myenteric nervous plexus and in the nucleus 
parasympathicus nervi X of the brain stem when naturally infected lambs are 9 months 
old (Andreoletti et al. 2000). The scrapie prions seem to reach the spinal cord at the 
same time since the PrPSc was detected in the dorsal motor nucleus of the vagus and the 
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intermediolateral column of the thoracic segments T8-T10 in naturally infected lambs at 
the age of 10 months (van Keulen et al. 2000).  
The presence of PrPSc in placentas from clinically scrapie-affected goats and ewes was 
demonstrated by mouse bioassays. PrPSc accumulation was detected in foetal chorion 
from pregnant scrapie-incubating ewes. Interestingly, the placenta from a scrapie-
incubating ewe can be found as PrPSc-positive in its first gestation and negative in the 
following gestation (Andreoletti et al. 2002). Moreover, Tuo et al. (2002) indicated that 
accumulation of PrPSc is eliminated or reduced to undetectable levels in reproductive 
and placental tissues if infected ewes are not pregnant or conceive conceptuses with  
a resistant PRNP genotype. 
 
2.4 The prion protein gene 
 
2.4.1 Gene structure 
 
The prion protein gene is located on the short arm of chromosome 20 in human, the 
syntenic region chromosome 2 in mouse (Prusiner 2004), and chromosome 13 in cattle 
and sheep (Castiglioni et al. 1998, Schlapfer et al. 1998). The gene structures of all 
species are similar. All of them contain three exons, which are separated by two large 
introns, and the coding regions (CDS) of all are located on exon 3. The length of the 
exons, introns and CDS of human, cattle, sheep and mouse PRNP are shown in Table 2 
 
Table 2:  Size (base pairs) of exons, introns and CDS of human, cattle, sheep and  
mouse PRNP  
 
Species Exon 1 Exon 2 Exon 3 CDS Intron 1 Intron 2 
Human1 134 99 2,354 762 2,622 9,975 
Cattle2 53 98 4,091 795 2,436 13,552 
Sheep3 52 98 4,028 771 2,421 14,031 
Mouse 
- long incubation time4 
- short incubation time5 
 
47 
47 
 
98 
98 
 
2,009 
2,153 
 
765 
765 
 
2,190 
2,190 
 
11,127 
17,733 
Reference number 1/ U29185, 2/ AJ298878, 3/U67922, 4/ U29187, 5/ U29186
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2.4.2 Polymorphisms of human, cattle and mouse PRNP 
 
In the human prion protein gene, a polymorphism at codon 129 encoding either 
methionine (M) or valine appears to influence human prion disease expression in the 
Caucasian population, not only in the inherited forms but also in the iatrogenic and 
sporadic forms. Genotype frequencies for the codon 129 polymorphisms in Caucasians 
are 12% V/V, 37% M/M and 51% M/V. In sixteen patients (fifteen white and one black) 
from United Kingdom, United States and France with iatrogenic CJD, eight (50%) were 
V/V, five (31%) were M/M, and three (19%) were M/V. Thus, a disproportionate 
number of patients with iatrogenic CJD were homozygous for valine at human PrP 
codon 129. This contrasts to the frequency of the V allele in the Japanese population 
which is much lower and heterozygosity at codon 129 is more frequent in Japanease 
CJD patients (18%) than in the general population where the polymorphisms are 0% 
V/V, 92% M/M and 8% M/V (reviewed in Prusiner 1996). Wadsworth et al. (2004) also 
reported that the generation of variant CJD in transgenic mice required expression of 
human prion protein with methionine 129; expression of human PrP with valine 129 
resulted in a distinct phenotype and persistence of a barrier to transmission of BSE-
derived prions on subpassage. In addition, the homozygosity for methionine at codon 
129 of the human PrP appears to influence the onset of neurological and hepatic 
symptoms in patients with the copper storage disorder Wilson disease as well (Merle  
et al. 2006).  
An insert of 144 bp containing six octarepeats at codon 53 (5 octarepeats are normally 
present) was described in patients with CJD from four families residing in southern 
England. It has been demonstrated that inserts of 2, 4, 5, 6, 7, 8 or 9 octarepeats in 
addition to the normal five are found in individual with inherited CJD. Moreover,  
a polymorphism resulting in substitution of glutamate (E) -> lysine (K) at codon 219 
has been reported in the Japanese (Shibuya et al. 1998) and Korean populations (Jeong 
et al. 2005). The lysine at codon 219 seems likely act dominant and protects against 
CJD over the glutamine in both populations. In addition, it seems that PrPC is not 
converted to PrPSc in the people carrying K/K genotype (reviewed in Prusiner 2004). 
Many polymorphisms of bovine PRNP have been reported as shown in Figure 5 (Sander 
et al. 2004). The positions of 60 polymorphisms detected in German cattle are indicated 
with respect to the PRNP reference sequence AJ298878. The nucleotide sequence 
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variants detected in the coding region of the bovine PRNP are a variation in the number 
of octapeptide repeats and the substitution of base G -> A, C -> T and C->T at position 
numbers 234, 339 and 576 of the coding region, respectively. For the octapeptide 
repeats polymorphism, most cattle have five repeats, but some have six repeats 
(Goldmann et al. 1991b, Hunter et al. 1994) and even seven repeats in Swiss brown 
cattle (Schlapfer et al. 1999). The amino acid sequences of the octapeptide repeats are 
Pro-His-Gly-Gly-Gly-Try-Gly-Gln or its longer variants Pro-Gln/His-Gly-Gly-Gly-Gly-
Try-Gly-Gln (see amino acid abbreviations in Appendix 1). In contrast to human and 
sheep, no bovine PRNP polymorphism associated to the prion disease has been 
reported. An analysis of 370 cattle in Scotland revealed no difference between the 
frequencies of the PRNP octapeptide repeats genotypes (6/6, 6/5 and 5/5 repeats) in 
healthy cattle and cattle with BSE (Hunter et al. 1994). Eventhough significant 
differences in allele frequencies for the 23 bp insertion/deletion (indel) and 12 bp indel 
polymorphisms (Figure 5) were observed in comparison between healthy and BSE 
infected German cattle (Sander et al. 2004), these differences were not found in 
Holstein cattle in Japan (Nakamitsu et al.2006). 
 
Figure 5: Diagram illustrating the genomic architecture of the bovine PRNP.  
(a) The positions of 60 polymorphisms detected in German cattle. (b) The three PRNP 
exons are presented by black boxes; the protein coding region is shown as a hatched box  
 
In mouse, classical genetic analysis of the control of ME7 scrapie agent incubation 
period identified the presence of a single gene encoding two alleles; s7 for the one 
which shortens the incubation time (180-200 days) and p7 for the one which prolongs 
the incubation time (300 days or more) (DeArmond and Prusiner 1996, Dickinson et al. 
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1968). It has been shown that these two alleles have an association to the 
polymorphisms at codons 108 [leucine (L) -> phenylalanine (F)] and 189 [threonine (T) 
-> valine] of the murine PRNP. Threonine at codon 189 is retained in mouse strains 
carrying allele s7 but is absent in mice carrying p7. At codon 108, mice with short 
incubation time encode leucine while mice with long incubation time encode 
phenylalanine. The association between these two polymorphisms and incubation 
period of prion disease in mice was supported by Barron et al. (2005) which presented 
that both codons 108 and 189 control TSE incubation time and that each polymorphism 
plays a distinct role in the disease process. 
 
2.4.3 Polymorphisms of ovine PRNP and association to scrapie susceptibility 
 
In sheep, within the PRNP coding sequence, several polymorphisms have been 
identified up to date as described in Table 3 (DeSilva et al. 2003, Lan et al. 2006, 
Seabury and Derr 2003, Tranulis 2002). The polymorphisms at codons 136 [alanine (A) 
or valine(V)], 154 [histidine (H) or arginine (R)] and 171 [glutamine (Q), arginine or 
histidine] of the ovine PRNP have been found to be linked with phenotypic expression 
differences of scrapie including incubation period, clinical signs and pathology. On the 
other hand, further polymorphisms are rare, and no association between these 
polymorphisms and any disease phenotype has been reported (Tranulis 2002). The 
presence of valine at codon 136 was detected mostly in natural scrapie-infected sheep 
and is believed to be associated with high susceptibility to scrapie and short survival 
times. Whereas alanine at codon 136, which was found mostly in healthy sheep of the 
same flocks, is believed to be linked to resistance or incubation times that span beyond 
the lifetime of sheep (Hunter et al. 1996, 1993, 1994, Laplanche et al. 1993, Tranulis  
et al. 1999). The polymorphism at this position appears, in addition, to be associated to 
control the disease incidence and to modulate the incubation period even in 
experimentally induced scrapie sheep (Goldmann et al. 1991a, Maciulis et al. 1992). 
Clouscard et al. (1995) and Tranulis et al. (1999) demonstrated that the major genetic 
factor controlling the susceptibility to natural scrapie in sheep is also represented by 
glutamine at codon 171 of the PRNP. Even the PRNP allele encoding valine at codon 
136 confers a high risk of scrapie in many sheep breeds, in some breeds i.e. Suffolk 
breed, this allele is vanishingly rare. Hunter et al. (1997) showed that in a single closed 
Literature review                                                                                                                                          21 
 
flock of Suffolk sheep in Scotland, scrapie occurred primarily in animals which were 
homozygous for glutamine at codon 171, a genotype which is significantly less frequent 
in healthy flocks. Moreover, O'Rourke et al. (1997) presented that after being inoculated 
orally with a scrapie agent into a Suffolk flock, all sheep developing scrapie during the 
observation period were homozygous for the glutamine at codon 171, whereas all 
homozygous for arginine and heterozygous remained free of scrapie. There was only 
one homozygous for arginine at codon 171 diagnosed with scrapie in Japan reported by 
Ikeda et al. (1995).  
The association between susceptibility to scrapie and the polymorphism at codon 154 is 
unclear; however, there was evidence suggesting that a histidine substitution at codon 
154 enhances the resistance to scrapie (Elsen et al. 1999, Thorgeirsdottir et al. 1999, 
Tranulis et al. 1999). 
 
Table 3: Polymorphisms in the coding region of ovine PRNP 
 
Codon number Amino acid variant Codon number Amino acid variant 
851 G <-> R 1461 N <-> S 
1011 Q <-> R 1512 R <-> C 
1122 M <-> T 1542 R <-> H 
1163 A <-> P 1674 R <-> S 
1272 G <-> S 1712 Q <-> K 
1362 A <-> T 1712 Q <-> R or H 
1362 A <-> V 1762 N <-> K 
1372 S <-> A 1804 H <-> Y 
1382 M <-> T 1891 Q <->L 
1384 S <-> R 1954 T <-> S 
1412 L <-> F 1964 T <-> S 
1432 H <-> R 2112 R <-> Q 
1 Lan et al. (2006), 2 Tranulis (2002), 3 Seabury and Derr (2003), 4 DeSilva et al. (2003) 
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2.4.4 Ovine PRNP genotypes and risk groups 
 
From the three polymorphisms of ovine PRNP described above, twelve alleles are 
possible derivable, but only five alleles are commonly seen. They are A136R154R171, 
A136R154Q171, A136R154H171, A136H154Q171 and V136R154Q171. The underscript numbers 
present the order of amino acid, here after ARR, ARQ, ARH, AHQ and VRQ, 
respectively (Belt et al. 1995, Tranulis 2002). In natural scrapie flocks, the VRQ allele 
was detected with high frequency in scrapie affected sheep, whereas the ARR variant 
was almost exclusively present in the healthy sheep of the flock-mates and believed to 
be associated with resistance to developing the clinical signs of scrapie (Belt et al. 1995, 
Goldmann et al. 1994, O'Doherty et al. 2002, Thorgeirsdottir et al. 1999). A study of 
Bossers et al. (1996) demonstrated that sheep with at least one AR allele (polymorphic 
amino acids at codons 136 and 171 are indicated) did not develop scrapie. 
For the rest of the alleles, ARH allele is likely to be neutral, while the AHQ allele 
decreased the risk of developing scrapie. The AHQ allele was not found in scrapie-
affected animals in Icelandic sheep (Thorgeirsdottir et al. 1999, 2002, Tranulis 2002). 
However, VRQ and ARR alleles act dominant over the ARQ and ARH alleles. The 
mechanisms by which the different PRNP alleles contribute to differences in scrapie 
susceptibility and incubation time are not clear.  
 
Table 4: Ovine PRNP genotypes and risk groups according to the polymorphisms 
at codons 136, 154 and 171 
 
Risk group Genotype 
R1 ARR/ARR 
R2 ARR/AHQ, AHQ/AHQ 
R3 ARR/ARQ, ARR/ARH, ARQ/AHQ, 
ARH/AHQ 
R4 ARH/ARH, ARQ/ARH, ARQ/ARQ, 
VRQ/ARR, VRQ/AHQ 
R5 VRQ/ARQ, VRQ/ARH, VRQ/VRQ 
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Based upon the common five alleles, fifteen genotypes have been investigated (Table 
4). These genotypes have been divided into five risk groups according to the 
susceptibility to scrapie. The ARR/ARR genotype (risk group 1, R1) is classified as 
resistant to scrapie group, while the VRQ/ARQ, VRQ/ARH and VRQ/VRQ genotypes 
(risk group 5, R5) are classified into the high susceptible group (Erhardt et al. 2002). 
 
2.4.5 Expression of PRNP mRNA 
 
PRNP mRNA is predominantly expressed in many regions of the central nervous 
system (CNS) of humans and animals (Han et al. 2006, Harris et al. 1993, Kubosaki et 
al. 2000, Manson et al. 1992, McLennan et al. 2001, Tichopad et al. 2003). In the brain, 
the mRNA was predominantly localised within pyramidal cells of the hippocampus, 
large neurons of the thalamus and neocortex, and Purkinje cells of the cerebellum (Tanji 
et al. 1995). In the septum, the levels of PRNP transcripts and choline acetyltransferase 
were found to increase in parallel during development (reviewed in Prusiner 2004).  
In non-neuron tissues, PRNP mRNA was observed in spleen, lymph nodes, thymus, 
muscle, liver, kidney and lung of sheep and cattle (Han et al. 2006, Tichopad et al. 
2003), but unable to be detected in kidney and liver of mice (Miele et al. 2003). The 
gene transcript was also found in reproductive tissues such as caruncle, myometrium, 
stratum longitudinale tunicae muscles and circular layers of muscular tunics of ewes 
(Kubosaki et al. 2000), and in spermatogenic cells of mice (Fujisawa et al. 2004).  
During embryogenesis, PRNP transcripts were found in developing brain and spinal 
cord of embryonic day 13.5 as well as in ganglia and nerves of the central and 
peripheral nervous system of embryonic day 16.5 in mice. The gene transcript was also 
detected in extra-embryonic tissues from day 6.5 and in specific non-neuronal cell 
populations such as intestine, dental lamina, tooth bud and kidney of the 13.5 and 16.5 
day embryos. However, no PRNP transcript could be detected by days 6.5 and 9.5 of 
mouse embryogenesis (Manson et al. 1992). This is in contrast to the later study of 
Miele et al. (2003), who represented the expression of PRNP mRNA in developing 
neurons of mice since days 8.5 to 9.5. In chicken, mRNA for a chicken PrP was 
detected in the brain and spinal cord as early as day 6 (the earliest stage studied) and 
was also found in dorsal root ganglia, retina, intestine and heart of day 11 embryos 
(Harris et al. 1993). 
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3 Material and methods 
 
This study was started with the PRNP genotyping in sheep of various breeds according 
to the reported polymorphisms at codons 136, 154 and 171 (Tranulis 2002). The sheep 
were then classified into 5 risk groups as described in Erhardt et al. (2002). A number of 
resistant (R1) and high susceptible to scrapie (R5) ewes were selected and mated to ram 
of the same risk group. PRNP mRNA expression analysis was performed in 
preimplantation embryos by real time RT-PCR, in various reproductive tissues of 
pregnant ewes and various tissues of their conceptuses during prenatal stage using 
semiquantitative RT-PCR. Moreover, normal cellular prion protein (PrPC) was detected 
in reproductive tissues of pregnant ewes, 1-month-old foetuses and various tissues of  
2-month-old foetuses using western blotting. Localisation of the gene transcript and the 
protein was performed in adult ovaries and 1-month-old foetuses by in situ 
hybridisation and immunohistochemistry, respectively. 
 
3.1 Material 
 
3.1.1 Animals and sampling 
 
Sheep of various breeds were used for PRNP genotyping. However, after grouping and 
selection, Black head and Bentheimer breed were used for gene and protein expression 
analyses. All of the Bentheimer sheep were R5 genotypes, whereas most of the Black 
head sheep were R1 genotype. Immature oocytes, mature oocytes and in vivo embryos 
at morula stage were collected from specifically selected ewes using standard 
techniques and subjected to RNA isolation as mentioned in 3.2.4.1. In addition, foetuses 
and female reproductive organs such as ovary, oviduct, endometrium, myometrium and 
caruncle were collected from R1 and R5 ewes at the 1st, 2nd, 3rd and 5th month of 
pregnancy (n = 2 from each group). The foetuses at the 2nd, 3rd and 5th month were 
separated into single organs of brain, cotyledon, spinal cord, heart, intestine, liver, lung, 
muscle and spleen. The samples were snap frozen in liquid nitrogen and kept at -80°C 
until used for RNA isolation (in 3.2.4.2), fluorescence in situ hybridisation (in 3.2.9), 
western blotting (in 3.2.10) and immunohistochemistry (in 3.2.11).  
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3.1.2 Laboratory equipment 
 
Amersham Biosciences (Buckinghamshire, UK): 
 Ultraspec 2100 pro spectrophotometer 
Applied Biosystems (Foster City, CA, USA): 
 ABI Prism Sequence Detection System Instrument 
BioRad (Munich, Germany): 
 Electrophoresis, Power Supply PAC 3000, Power Supply Mini-Protran, 
Trans-Blot SD Semi-Dry Transfer Cell 
Carl-Roth (Karlsruhe, Germany): 
 Hellendahl jars, Rotilabo®-Probenröhrchen 
Heraeus (Hanau, Germany): 
 Incubator (BB16) 
Hermle (Wehingen, Germany): 
 Centrifuge 
Leica (Nussloch, Germany): 
 Cryostat CM 3050 S 
Li-cor Biotechnology (Lincoln, USA) 
 Li-cor autonated DNA sequencer (model 4200) 
MJ Research (USA): 
 PCR thermal cycler (PTC 100) 
Menzel-Gläser (Braunschweig, Germany): 
 SuperFrost Plus slide 
Schleicher & Schuell BioScience (Dassel, Germany): 
 Nitrocellulose transfer membrane (Protran, pore size 0.45 µm) 
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3.1.3 Biological materials, reagents, kits and buffers 
 
3.1.3.1 Biological materials 
 
Applichem (Darmstadt, Germany): 
 50x Denhardt’s solution 
Biomol (Hamburg, Germany): 
 Lambda DNA Eco91I (BstE II), Lambda DNA HindIII, Phenol 
Biozym Diagnostik (Hessisch-Oldendorf, Germany): 
 Sequagel XR sequencing gel, Sequagel complete buffer reagent 
Fermentas (St. Leon-Rot, Germany): 
 PageRuler™ Unstained Protein Ladder, Ribonuclease A, Ribonuclease T1 
Invitrogen (Karlsruhe, Germany): 
 Dynal beads Oligo (dT)25  
Kodak (Japan): 
 Autoradiography film (Kodak Biomax XAR film) 
Merck Eurolab GmbH (Darmstadt, Germany) 
 Kaiser’s glycerol gelatine, Hematoxylin 
MWG Biotech (Eberberg, Germany): 
 Oligonucleotide primers 
Promega (Mannheim, Germany): 
 Random primer, RQ1 RNase-free Dnase and 10x RNase-free buffer, 
RNasin® Ribonuclease inhibitor inhibitor, DTT 0.5 M 
Roche (Mannheim, Germany) 
 Fish sperm DNA, Horseradish peroxidase anti-digoxigenin antibody 
Roth (Karlsruhe, Germany): 
 Acetic acid, Agar-Agar, Ampicillin, Ammonium peroxydisulfate, Boric 
acid, 5-bromo-4-chloro-3-indolyl-β-D-galactopyra-noside (X-gal), 
Bromophenol blue, Chloroform, DEPC, Dimethyl sulfoxide (DMSO), Di-
sodium hydrogen phosphate dihydrate (Na2HPO4*2H2O), dNTPs set, 
Ethanol, Ethylenediamine tetra acetic acid di sodium salt, Ethidium 
bromide, 37% Formaldehyde, Formamide, Glycerine, Hydrochloric acid, 
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Hydrogen peroxide (30%), Isopropyl β-D-thiogalactoside (IPTG), 
Korsolin FF, Methanol, Mop, N,N´-dimethylformamide, Pepton, 
Proteinase K, Sodium acetate, Sodium chloride, Sodium di-hydrogen 
phosphate, Sodium dodecyl sulfate (SDS), Sodium hydroxide, TEMED, 
Tris, Tri-sodium-citrate*2H2O, Xylene cyanol, Yeast extract 
SERVA Electrophoresis GmbH (Heidelberg, Germany): 
 Acrylamide, Bisacrylamide 
Sigma-Aldrich Chemie GmbH (Taufkirchen, Germany): 
 Acetic anhydrid, Acetone, Agarose, 3-amino-9-ethylcarbazole (AEC), 6-
aminohexanoic acid, Blue dextran, Dextran sulphate, 
Dimethylformamide, Glycine, Guanidine hydrochloride, Igepal, 
Isopropanol, Lithium chloride, 2-Mercaptoethanol, Paraformaldehyde, 
Polyvinyl pyrolidone (PVP), Ponceau S, Protease inhibitor cocktail, Tag 
DNA polymerase and 10x Buffer, Triethanolamine, Tri Reagent, Tween® 
20, Yeast tRNA 
Stratagene (Amsterdam, NL): 
 5α DH Escherichia coli competent cells 
 
3.1.3.2 Kits 
 
Amersham Biosciences (Buckinghamshire, UK): 
 ECL Plus Western Blotting Detection 
Biozym Diagnostik (Hessisch-Oldendorf): 
 SequiTherm ExcelTMII DNA sequencing kit 
Invitrogen (Karlsruhe, Germany): 
 SuperscriptTM II RNase H- Reverse Transcriptase 
PerKin Elmer (Rodgau Juegesheim, Germany) 
 TSATM-Plus Fluorescein System 
Promega (Mannheim, Germany): 
 pGEM-T vector 
Qiagen (Hilden, Germany): 
 RNeasy Mini Kit  
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Roche (Mannheim, Germany): 
 DIG RNA labelling kit 
Santa Cruz Biotechnology (Heidelberg, Germany) 
 Mouse ABC Staining System 
Sigma (Steinheim, Germany): 
 GenEluteTM Plasmid Miniprep Kit 
SYBR Green JumpStartTM Tag ReadyMixTM 
 
3.1.3.3 Buffers and reagents 
 
All solutions were prepared with deionised and demineralised millipore water and pH 
was adjusted with sodium hydroxide (NaOH) or hydrochloric acid (HCl). 
 
General reagents   
   
DEPC-treated water: DEPC 1.00 ml 
 Water added to 1,000.00 ml 
 Incubate overnight at 37°C and heat inactivate by 
autoclaving 
 
dd H2O: Deionised millipore water   
 Autoclave (for in situ hybridisation) 
 
10x PBS: NaCl 87.67 g 
 Na2HPO4.2H2O 15.00 g 
 NaH2PO4 2.04 g 
 Water added to 1,000.00 ml 
 For in situ hybridisation, treat with 1 ml DEPC, incubate 
overnight at 37°C and heat inactivate by autoclaving 
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1x PBS: 10x PBS 100.00 ml 
 Water added to 1,000.00 ml 
 For in situ hybridisation, treat with 1 ml DEPC, incubate 
overnight at 37°C and heat inactivate by autoclaving 
 
1x PBS-Tween (PBST): 1x PBS 999.50 ml 
 Tween®20 
 
0.50 ml 
Tris-HCl (1 M): Tris 121.14 g 
 Water added to 1,000.00 ml 
 Adjust pH to the required pH 
 
  
EDTA (0.5 M, pH 8.0): 
 
Ethylendiamin tetra acetic acid 
disodium salt 
 
186.12 
 
g 
 Water added to 
 
1,000.00 ml 
EDTA (5 mM, pH 8.0) EDTA (0.5 M, pH 8.0) 10.00 ml 
 Water added to 
 
1,000.00 ml 
DNA isolation 
 
  
Digestion buffer: 9% NaCl 6.50 ml 
 Tris (1 M, pH 7.5) 5.00 ml 
 EDTA (0.5 M, pH 8.0) 0.20 ml 
 SDS (10%) 1.00 ml 
 Mercaptoethanol 
 
2.00 ml 
Proteinase K 10 mg/ml 
 
  
Phenol-Chloroform 1/1 (v/v) 
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1x TE buffer: Tris-HCl (1 M, pH 8.0) 0.50 ml 
 EDTA (0.5 M, pH 8.0) 0.10 ml 
 Water added to 
 
50.00 ml 
RNA isolation 
 
  
Binding buffer: Tris-HCl (1 M, pH 7.5) 1.00 ml 
 Lithium chloride (5 M) 10.00 ml 
 EDTA (5 mM, pH 8.0) 20.00 ml 
 Water added to 
 
50.00 ml 
Washing buffer: Tris-HCl (1 M, pH 7.5) 0.50 ml 
 Lithium chloride (5 M) 1.50 ml 
 EDTA (5 mM, pH 8.0) 1.00 ml 
 Water added to 
 
50.00 ml 
Protein isolation 
 
Guanidine  Guanidine hydrochloride 1.43 g 
hydrochloride (0.3 M): 95% Ethanol added to 
 
50.00 ml 
4x Sample loading  Tris (1 M, pH 6.8) 13.00 ml 
buffer: SDS 6.00 g 
 2-Mercaptoethanol 10.00 ml 
 Glycerine 20.00 ml 
 Bromophenol blue 10.00 mg 
 Water added to 
 
50.00 ml 
DNA electrophoresis 
 
  
50x TAE: Tris 242.00 g 
 Acetic acid 57.10 ml 
 EDTA (0.5 M, pH 8.0) 100.00 ml 
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 Water added to 
 
1.000.00 ml 
10x TBE: Tris 108.00 g 
 Boric acid 55.00 g 
 EDTA (0.5 M, pH 8.0) 40.00 ml 
 Water added to 
 
1,000.00 ml 
Blue dextran loading  Blue Dextran 50.00 mg 
buffer: EDTA (0.5 M, pH 8.0) 50.00 µl 
 Water 0.95 ml 
 Formamide 
 
5.00 ml 
PAA loading buffer: Formamide 47.50 ml 
 NaOH 0.40 g 
 Bromophenol blue 125.00 mg 
 Xylene cyanol 125.00 mg 
 Water added to 
 
50.00 ml 
RNA electrophoresis 
 
10x FA buffer (pH 7.0): MOPS 41.85 g 
 Sodium acetate 4.10 g 
 EDTA 20.00 ml 
 Water added to 1000.00 ml 
 1 litre of 1x FA buffer containing 20 ml of 37% 
formaldehyde 
 
1.5% FA gel: Agarose 1.50 g 
 10x FA buffer 10.00 ml 
 DEPC-treated water added to 100.00 ml 
 Boil for 3 to 5 min until agarose is completely dissolved, 
add 5µl of Ethidium bromide and 1.8 ml of 37% 
formaldehyde 
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Protein electrophoresis 
 
Anode buffer I: Tris-HCl (1 M, pH 10.4) 150.00 ml 
 Methanol 50.00 ml 
 Water added to 
 
500.00 ml 
Anode buffer II: Tris-HCl (1 M, pH 10.4) 12.50 ml 
 Methanol 50.00 ml 
 Water added to 
 
500.00 ml 
Cathode buffer: Tris-HCl (1 M, pH 9.4) 12.50 ml 
 Methanol 50.00 ml 
 6-aminohexanoic acid 3.94 g 
 Water added to 
 
500.00 ml 
Seperation gel (15%): 
 
Acrylamide/Bis-acrylamide  
[30%/0.8% (w/w)] 
7.50 ml 
 Tris-HCl (1 M, pH 8.8) 5.60 ml 
 SDS (10%) 0.15 ml 
 Water 1.75 ml 
 Temed 10.00 µl 
 APS (20%) 
 
30.00 µl 
Stacking gel: Acrylamide/Bis-acrylamide  
[30%/0.8% (w/w)] 
1.50 ml 
 Tris-HCl (1 M, pH 6.8) 1.30 ml 
 SDS (10%) 0.15 µl 
 Water 7.05 ml 
 Temed 10.00 µl 
 APS (20%) 
 
 
 
30.00 µl 
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10x Running buffer: Tris 30.30 g 
 Glycine 144.00 g 
 SDS 10.00 g 
 Water added to 
 
1,000.00 ml 
0.2% Porceau S: Ponceau S 1.00 g 
 Acetic acid 50.00 ml 
 Water added to 
 
500.00 ml 
Cloning 
 
Amplicillin: Amplicillin 10.00 mg 
 Sterilized water 
 
1.00 ml 
IPTG solution (0.5 M): IPTG 1.20 g 
 Water added to 10.00 ml 
 Filter-sterilize and store at -20°C 
 
LB-agar plate: NaCl 8.00 g 
 Peptone 8.00 g 
 Yeast extract 4.00 g 
 Agar-agar 12.00 g 
 NaOH (1 N) 0.48 ml 
 Water added to 800.00 ml 
 Autoclave-sterilize 
 
LB-broth: NaCl 8.00 g 
 Peptone 8.00 g 
 Yeast extract 4.00 g 
 NaOH (1 N) 0.48 ml 
 Water added to 800.00 ml 
 Autoclave-sterilize 
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X-Gal working solution: X-Gal 50.00 mg 
 N, N´-dimethyl-formamide 1.00 ml 
 Store at -20°C. 
 
In situ hybridisation 
 
50% Dextran sulphate: Dextran sulphate 2.00 g 
 DEPC-treated H2O 2.50 ml 
 Leave to dissolve overnight. Adjust to 4.0 ml with DEPC-
treated H2O. Prepare always fresh in 25.0 ml measuring 
cylinder one day prior to preparation of hybridisation 
buffer 
 
70% DMF: Dimethylformamide (DMF) 3.50 ml 
 DEPC-treated H2O 1.50  ml 
 Prepare fresh 
 
  
Hybridisation buffer: 50% Dextran sulphate 4.00 ml 
 NaCl (2.5 M) 1.20 ml 
 Formamide, deionised 10.00 ml 
 20x SSC 2.00 ml 
 Yeast tRNA (10 mg/ml) 0.40 ml 
 50x Denhardt's solution 0.40 ml 
 Fish sperm DNA (10 mg/ml) 2.00 ml 
 Mix thoroughly, wait until air bubbles have disappeared, 
and store 1 ml aliquots at -20°C 
 
NaCl (2.5 M): NaCl 14.61 g 
 Water added to 100.00 ml 
 Treat with 0.1% (100 µl) DEPC, incubate overnight at 
37°C and heat inactivate by autoclaving 
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4% PFA (pH 7.3): Paraformaldehyde 10.00 g 
 1 x PBS added to 250.00 ml 
 Bring to 65°C under ventilation hood, add 5 µl of 5 M 
NaOH for solution to become clear, store protected from 
light and use within 2 weeks 
 
20x SSC (pH 7.0): NaCl 87.66 g 
 Tri-Na-citrate*2 H2O 44.12 g 
 Water added to  500.0 ml 
 Treat with 1% (500 µl) DEPC. Incubate overnight at 37°C 
and heat inactivate by autoclaving 
 
2x SSC: 20x SSC 100.00 ml 
 DEPC-treated water  
 
900.00 ml 
0.1 M TEA buffer  Triethanolamine 13.20 ml 
(pH 8.0): DEPC-treated water added to 1,000.00 ml 
 Autoclave. Store at RT protected from light 
 
TNB blocking buffer: Blocking reagent 0.50 g 
 TN buffer 100.00 ml 
 Add blocking reagent slowly in small increments to TN 
buffer while stirring, if necessary heat to 60°C to dissolve 
completely. Store aliquots at -20°C 
 
TN buffer (pH 7.5): Tris 12.11 g 
 NaCl 8.77 g 
 Water added to 
 
1,000.00 ml 
TNT wash buffer: TN buffer 995.00 ml 
 10% Tween 20 
 
 
5.00 ml 
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10% Tween 20: DEPC-treated H2O 45.00 ml 
 Tween®20 
 
5.00 ml 
Yeast tRNA (10 mg/ml): Yeast tRNA 25.00 mg 
 DEPC-treated H2O 2.50 ml 
 Dissolve by incubating on ice for at least 1 h.  
Store aliquots at -20°C. 
 
Immunohistochemistry 
 
   
AEC stock solution: AEC 100.00 mg 
 DMF 10.00 ml 
 Store at 4°C and protect from light 
 
AEC substrate (10 ml): AEC stock solution 0.50 ml 
 Sodium acetate (50 mM, pH 5.0) 9.50 ml 
 Sodium hydroxide (30%) 
 
5.00 µl 
Sodium acetate  Sodium acetate 4.10 g 
(50 mM, pH 5.0): Water added to 1000.00 ml 
 
3.1.4 Sources of software and Internet facilities 
 
ABI Prism Sequence Detection System 
Software 
Applied Biosystems  (Foster City, USA) 
BLAST program  http://www.ncbi.nlm.nih.gov/blast/  
Image analysis program (version 4.10)   Li-cor Biotechnology (Lincoln, USA) 
Multiple sequence alignment  http://prodes.toulouse.inra.fr/multalin/ 
multalin.html  
Primer Express Software version 2.0 Applied Biosystems (Foster City, USA) 
SAS version 8.0  SAS Institute Inc. (Cary, NC) 
Weight to Molar Quantity (for nucleotide)  http://www.molbiol.ru/eng/scripts/ 
01_07.html  
Table 5: Details of primers used for amplification and sequencing 
 
Genes Primer sequence (5´-3´) 
Position within 
ref sequence 
Product 
size (bp) 
Annealing 
temperature (°C) 
Accession 
number 
Ovine PRNP 
(external) a 
TCAGTGGAACAAGCCCAGTAAGC 
GGTGGTGACTGTGTGTTGC 
22577 
22859 
283 
Touch down 
64-58 
U67922 
Ovine PRNP 
(internal) b 
AGCTGGAGCAGTGGTAGG 
GTGATGTTGACACAGTCATGC 
22637 
22814 
198 60 U67922 
Ovine PRNP  c, d 
CCAAGCTGAAGCATCTGTCTTCC 
TCACTCCACATGGCCACAAAG 
89 
219 
131 58 NM_001009481 
Ovine H2a d 
CACCTCAAATCTAGGACGACTAGCC 
CGATGCATTTCCTGCCAATTC 
210 
326 
117 60 AY074805 
18S-rRNA c, d 
GCGCGCAAATTACCCAC 
GCTGGAATTACCGCGGCT 
89 
247 
159 54 AF176811 
a
 The primer used for DNA amplification in genotyping procedure, b The primer used for PRNP sequencing, 
c
 The primer used for RT-PCR, d The primer used for real time PCR 
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3.2 Methods 
 
3.2.1 Primers design 
 
All of the primers used in this study were designed for PCR amplification and in vitro 
transcription using Primer Express® Software v2.0 (Applied Biosystems, Foster City, 
CA, USA). Primer sequences, size of amplified products, annealing temperature and the 
GenBank accession number are shown in Table 5. 
 
3.2.2 PRNP genotyping 
 
3.2.2.1 Blood sampling 
 
To identify the PRNP genotype of ewes and rams, 10 ml of blood was taken from the 
jugular vein of the animal, kept in a tube containing 500 µl of 0.5 M EDTA as an 
anticoagulant and chilled immediately on ice. After centrifugation of blood samples at 
1,100 rpm for 30 min, the blood was separated into: 1) a lower red blood cell phase,  
2) a middle phase of white blood cells, and 3) a colourless upper aqueous phase of 
plasma. The middle layer was transferred to a new sterile 15 ml tube. Nine ml of 
deionised and demineralised water was added to the sample and the mixture was then 
mixed by inversion for 20 sec followed immediately by adding 1 ml of 9% NaOH. The 
mixture was centrifuged at 1,100 rpm for another 15 min. Supernatant was discarded 
and the pellet was used for DNA isolation. 
 
3.2.2.2 DNA extraction from blood samples 
 
Genomic DNA from blood samples of sheep was isolated using standard 
phenol/chloroform extraction method. All centrifugation steps were conducted at 12,000 
x g. To the white blood cell pellet from previous step 0.7 ml of digestion buffer and  
20 µl of proteinase K were added. The mixture was incubated at 50°C overnight at 100 
rpm in a shaking incubator. Complete pellet digestion resulted in a viscous 
homogeneous solution. An equal volume of phenol-chloroform was added and mixed 
by several inversions. The sample was then centrifuged for 10 min at room temperature. 
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After centrifugation, the sample was separated into: 1) a lower phenol-chloroform 
phase, 2) an interphase of protein and 3) an upper aqueous phase of DNA. The aqueous 
phase was transferred into a 2.0 ml microcentrifuge tube and washed by mixing with an 
equal volume of chloroform to remove residual phenol. After centrifugation for another 
10 min at room temperature, the DNA containing the aqueous phase was transferred to  
a new 2.0 ml tube and precipitated by mixing with 1/10 volume of sodium acetate (3 M, 
pH 8.5) and a double volume of isopropanol. The mixture was incubated overnight at -
20°C or 2 hours at -80°C followed by centrifugation for 20 min at 4°C. Then, the 
supernatant was drained and the pellet was washed with 0.5 ml of 75% ethanol to 
remove excess salt. After centrifugation for another 10 min at 4°C, the DNA pellet was 
briefly air dried and dissolved in 0.3 to 0.5 ml of 1x TE buffer. The DNA concentration 
was measured by the formula: 50 x absorbance at 260 nm x dilution factor. A value of 
more than 1.5 of the absorbance 260/280 ratio and integrity of high molecular weight 
indicates a good quality of DNA. A working DNA solution was prepared by diluting 
stock DNA with 1x TE buffer to the concentration of 50 ng/µl. The stock DNA solution 
was kept at -20°C and the working solution was kept at 4°C. 
 
3.2.2.3 PCR amplification 
 
The ovine PRNP was amplified using Ovine PRNP (external) primers (Table 5). PCR 
was performed by combining 2 µl of working DNA solution and 18 µl of master mix 
containing 2 µl of 10x PCR buffer, 0.5 µl of dNTPs (10 pmol/µl), 0.5 µl of each primer 
(10 pmol/µl) and 0.2 µl of Taq polymerase (5 units/µl). The thermal cycler PTC (MJ 
Research Inc.) was used to run the PCR at 94°C for 5 min followed by 35 cycles of 
94°C for 30 sec, 58°C for 30 sec and 72°C for 30 sec, a final extension step was run at 
72°C for 5 min. Five microlitre of the PCR product was electrophoresed on a 1.5% 
agarose gel and UV-Transilluminator’s documented. The rest of the PCR product was 
kept at 4°C for the next step of sequencing.  
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3.2.2.4 Sequencing 
 
Direct DNA sequencing was employed to genotype the PRNP polymorphisms as 
previously described by using the SequiTherm EXCELTM II DNA Sequencing Kit 
(Biozym Diagnostik, Germany) and LI-COR automated DNA sequencer (LI-COR 
Biotechnology, USA). The sequencing was performed by dye the termination method. 
The primers used were fluorescent labelled primers [Ovine PRNP (internal) primers, 
Table 5] which can be read by laser of the sequencer. For each sample, four reactions 
were performed; each reaction had one dideoxy nucleotide termination mix (ddATP, 
ddTTP, ddCTP and ddGTP) which would terminate the elongation reaction once the 
nucleotide binds to the elongating strand. Each reaction consists of 1 µl of termination 
mix and 2 µl of premix solution [3.6 µl of 3.5x Excel II sequencing buffer, 0.25 µl of 
forward primer (10 pmol/µl), 0.25 µl of reverse primer (10 pmol/µl), 0.5 µl of Taq 
polymerase (5 units/µl) and 3.9 µl of PCR product from step 3.2.2.3]. The reaction was 
run on a thermocycler at 94°C for 5 min followed by 20 cycles of 94°C for 20 sec, 60°C 
for 20 sec and 68°C for 20 sec. Immediately after PCR, 1.5 µl of stop buffer was added 
and the product was stored at –20oC till loading. The sequencing reactions were 
denatured at 90°C for 5 min and immediately loaded onto the 41 cm 6% Sequagel-XR 
(Biozyme Diagnostik, Germany). Electrophoresis was performed on a LI-COR model 
4200 automated DNA sequencer in 1x TBE buffer at 50°C, 50 W and 1500 V.  
Sequence data was analysed by using the Image Analysis program, version 4.10 (LI-
COR Biotechnology). 
 
3.2.3 Oocytes and in vivo embryo collection 
 
Ovaries and uteri were taken from specifically mated ewes at a specific time range. The 
ovaries were removed and kept in 35°C warm 0.9% physiological salt solution 
supplemented with 0.5 ml Streptocombine® per litre. Before aspiration of cumulus 
oocyte complexes (COCs), the ovaries were washed once in 70% ethanol followed by 
two times of washing in 0.9% salt solution. The COCs were aspirated from follicles 
using 5 ml syringe attached with 18G needle. The follicle fluid was allowed to 
precipitate for 15 min and the competent COCs were picked out using a glass pipet. For 
the morula stage embryo collection, ewes were slaughtered and the uteri were dissected 
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at the uterotubal junction and the cervix. Both uterine horns were divided at the 
bifurcation and flushed with 40 to 50 ml of Phosphate buffer saline (PBS, 39°C) each. 
After precipitation, the embryos were picked using a glass pipet. A total of 3 to 5 
oocytes and single embryos were washed two times with PBS and treated with acidic 
Tyrode pH 2.5 to 3 to dissolve the zona pellucida. The zona free oocytes and embryos 
were snap frozen in cryotubes containing 1.5 µl of lysis buffer [0.8% Igepal, 1 U/µl 
RNasin, 5 mM DTT], before storage at –80°C for the further work of RNA isolation. 
 
3.2.4 RNA isolation and cDNA synthesis  
 
3.2.4.1 Oocytes and preimplantation embryos 
 
RNA isolation  
 
Three independent pools of each containing 15 to 20 immature oocytes or 3 embryos 
were used for mRNA isolation using oligo (dT)25 attached magnetic beads following 
the manufacturer’s instruction. Briefly, samples in lysis buffer were mixed with the total 
volume of 40 to 60 µl of binding buffer and incubated for 5 min at 70°C to obtain 
complete lysis of the sample. Twenty microlitres of oligo(dT) magnetic bead suspension 
was washed twice with double volume of binding buffer and resuspensed in 4 µl of 
binding buffer before added to the samples. The mixture was then incubated for 30 min 
at room temperature and chilled on ice after this step until finish. The hybridised mRNA 
and oligo(dT) magnetic beads were washed three times with 100 µl of washing buffer. 
Finally, mRNA samples were eluted in 11 µl of DEPC-treated water and heated at 90°C 
for 4 min.  
 
cDNA synthesis 
 
The mRNA samples were reverse transcribed in 20 µl reaction volume containing 1 µl 
of oligo dT(12)N primer (where N = G, A or C), 1 µl of random primer (500 ng/µl),  
4 µl of 5x first strand buffer, 2.5 µl of 0.1 M DTT, 1 µl of each dNTPs (40 pmol/µl) and 
RNase inhibitor, and 0.5 µl of SuperScript II reverse transcriptase (200 unit/µl). In 
terms of the order of adding the reaction components, mRNA, random primer and 
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oligo(dT) primer were mixed and heated for 5 min at 70°C. The mix was placed on ice 
until the addition of the remaining reaction components and then incubated for 90 min 
at 42°C. The reaction was terminated by heat inactivation for 15 min at 70°C. The 
cDNA solution was kept at -20°C until used for gene expression analyses using real 
time PCR technique.  
 
3.2.4.2 Tissue samples 
 
RNA isolation 
 
Total RNA was isolated from tissue samples using TRIZOLE Reagent following the 
manufacturer’s instruction. The tissue samples stored at –80°C were taken out just 
before isolation. About 30 to 40 mg of tissue was ground by using mortal and pestle, 
and incubated with 1 ml of TRIZOL for 5 minutes at room temperature to permit 
complete dissociation of nucleoprotein complexes. The clear homogenate was then 
mixed with 0.2 ml of chloroform and vigorously shaken by hand for 15 sec. After 
centrifugation at 12,000 x g for 15 min at 4oC, the mixture was separated into:  
1) a lower red phenol-chloroform phase, 2) a white interphase and 3) a colorless upper 
aqueous phase containing RNA. The aqueous phase was transferred to a fresh 2.0 ml 
tube and the RNA was precipitated by adding 0.5 ml of isopropanol. The sample was 
then incubated at room temperature for 10 min and centrifuged at 12,000 x g for 10 min 
at 4oC. After centrifugation, the RNA precipitate becomes visible as white pellet at the 
bottom of the tube. The supernatant was drained off and the pellet was washed once 
with 1 ml of 75% ethanol before being centrifuged at 12,000 x g for 5 min at 4°C. The 
ethanol supernatant was removed and the RNA pellet was briefly air dried for 5 to 10 
min and dissolved with 22 µl of DEPC-treated H2O. The quality of RNA was checked 
by running 2 µl of total RNA in 1.5% FA gel.  
 
DNase digestion and RNA purification  
 
All good quality RNA samples were subjected to DNase digestion to avoid the residual 
DNA by mixing 20 µl of RNA extract with the premix of 7.5 µl of deoxyribonuclease I 
(RQ1 DNase), 4 µl of 10x RQ1 buffer, 1 µl of RNase inhibitor and 7.5 µl of DEPC 
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treated water. The mixture was incubated for 1 hour at 37°C. The digested RNA was 
purified using RNeasy mini kit (Qiagen, Germany) following the manufacturer’s 
instruction. The quality of the RNA was checked by running 2 µl of total RNA in 1.5% 
FA gel. The OD spectrometer value was taken to estimate the concentration of total 
RNA by the formula: 40 x absorbance at 260 nm x dilution factor. A working RNA 
solution was prepared by diluting stock RNA with DEPC-treated H2O to the 
concentration of 200 ng/µl. Both of stock and working RNA solution was kept at -80°C 
for further use. 
 
cDNA synthesis 
 
One microgram of total RNA was reverse transcribed using reverse transcriptase to 
synthesize cDNA. Five microlitre of total RNA working solution and 1 µl of each oligo 
dT(12)N (100 pmol/µl) and random primers (500 ng/µl) were added in a 0.2 ml PCR 
tube. The mixture was incubated for 5 minutes at 70°C and then immediately chilled on 
ice. Thirteen microlitre of the premix containing 4 µl of 5x first strand buffer, 2.5 µl of 
0.1 M DTT, 5 µl of dNTPs (10 pmol/µl) and 1 µl of each RNase inhibitor and 
SuperScriptIITM reverse transcriptase (200 unit/µl) was mixed and incubated for 90 
minutes at 42oC followed by heat inactivation for 15 min at 70°C. The synthesized 
cDNA was diluted with 150 µl of DEPC-treated H2O and stored at –20oC for further 
use.  
 
3.2.5 Semiquantitative PCR 
 
Polymerase chain reaction was used to quantify the amount of gene transcript in sample 
tissues. In this study the levels of 18S-rRNA transcript were used as an internal 
standard. The appropriate cycle number of PCR was pre-optimised. Each cDNA source 
was done in duplicate to control the reproducibility of results. Ovine PRNP PCR was 
performed using Ovine PRNP primers, and 18S-rRNA PCR was done using the 18S-
rRNA primers (Table 5). The thermo cycle condition of ovine PRNP PCR was 
programmed at 94°C for 5 min followed by 28 cycles of 94°C for 30 sec, 58°C for 30 
sec, 72°C for 30 sec and a final extension step of 72°C for 5 min. The 18S-rRNA PCR 
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was performed using cycles of 94°C for 5 min, 15 cycles of 94°C for 30 sec, 54°C for 
30 sec and 72°C for 30 sec followed by a final extension step of 72°C for 5 min. 
 
3.2.6 Plasmid DNA preparation 
 
3.2.6.1 PCR amplification 
 
The ovine PRNP, histone H2a and 18S-rRNA PCR for plasmid DNA preparation were 
amplified by using Ovine PRNP, Ovine H2a and 18S-rRNA primers, respectively,  as 
shown in Table 5. cDNA from adult brain was used as template for every reaction. The 
PCR reaction was combined as described in step 3.2.2.3 and the thermo cycler was 
programmed at 95°C for 5 min followed by 35 cycles of denaturing at 94°C for 30 sec, 
annealing at temperatures as indicated in Table 5 for 30 sec and extension at 72°C for 
30 sec. Following the last cycle, a 5 min elongation step at 72°C was performed.  
 
3.2.6.2 PCR product extraction 
 
The PCR product was extracted from agrose gel using basic method base on phenol-
chloroform extraction. All the centrifugation steps were carried out at 12,000 x g at 4°C. 
Briefly, the PCR fragment was electrophoresed and sliced out from the 1.0% agarose 
gel. The gel slice was frozen in a 1.5 ml microcentrifuge tube for 30 min at -20°C and 
chopped into small pieces. The gel was then homogenized with 0.5 ml of 1x TE buffer 
by repeatedly forcing through a syringe and needle. The extraction was carried out by 
vigorously vortexing the gel solution with 0.6 ml of phenol-chloroform. By 
centrifugation for 15 min, the mixture was separated into a lower phenol-chloroform 
phase, an interphase of precipitated protein, and an upper aqueous phase containing the 
PCR product. The aqueous phase was taken to a fresh tube, shaken with an equal 
volume of chloroform to remove possibly carried over phenol, and recentrifuged for 
another 10 min. The clear aqueous phase was precipitated by gentle mixing with 50 µl 
(or 1/10 volume) of sodium acetate solution (3 M, pH 5.3) and 1.5 ml of 100% ethanol 
(or 2.5 volume). Precipitation was maximized by placing at -20°C for 2 hour. The 
precipitated PCR product was pelleted at 12,000 x g for 30 min at 4°C. The supernatant 
was then removed and the pellet was washed with 1.0 ml of 70% ethanol to remove 
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excess salt. The mixture was recentrifuged to remove the supernatant and then the pellet 
was air dried briefly. Finally, the pellet was gently dissolved in 7 µl of ddH2O. 
 
3.2.6.3 Ligation 
 
The pGEM®-T Vector System I ligation kit was used. The ligation was performed by 
mixing 2.5 µl of 2x ligation buffer, 1.5 µl of gel purified PCR product, 0.5 µl of pGEM 
vector (50 ng) and 0.5 µl of T4 DNA ligase (3 units/µl), and by an incubation for  
2 hours at 20°C or overnight incubation at 4°C. 
 
3.2.6.4 Competent cell preparation 
 
Competent cells were prepared from stock bacteria E. coli strain DH5α (Clontech). 
Stock solution of bacteria was streaked on LB plate without ampicillin and incubated 
overnight at 37°C. A single colony was picked and inoculated in 50 ml of LB broth 
(without ampicillin). Inoculums were shaken gently at 37°C approximately 6 hours, 
during this OD was periodically measured to keep the OD no more than 0.3. Then, the 
cell culture was centrifuged at 5,000 x g for 10 min at 4°C. The pellet was resuspended 
in 25 ml of cold sterile 0.1 M CaCl and incubated on ice for 20 min. The cells were 
recentrifuged at 5,000 x g for 5 min at 4°C and then resuspended in 5 ml of 0.1 M CaCl 
containing 20% glycerol. The cell suspension was aliquoted into 1.5 ml microcentrifuge 
tubes and stored at -80°C. 
 
3.2.6.5 Transformation 
 
Transformation was performed by combining 60 µl of competent E. coli cells DH5α and 
5 µl of ligation reaction in a 15 ml falcon tube and incubating on ice for 30 min. After 
incubation, heat-shock was performed by placing the tube for 90 sec in water bath at 
exactly 42°C and immediately returning to ice bath for 2 min. Then, 0.7 ml of LB broth 
was added to the reaction and the mixture was shaken 110 rpm for 90 min at 37 °C.  
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3.2.6.6 Clonning 
 
Two LB-ampicillin plates were used for each ligation solution. The plates were 
prepared 30 min prior to use by spreading 20 µl of 0.5 M IPTG and 20 µl of 50 mg/ml 
X-Gal over the surface of LB-ampicillin plates with a glass spreader. The bacteria 
culture was then plated onto duplicate LB-ampicillin plates and incubated overnight 
(~16 hours) at 37°C until colonies are visible. Successful cloning of an insert in the 
pGEM-T vectors interrupts the coding sequence of β-galactosidase, hence the vectors 
with insert produce white colour colonies in plate having X-gal medium against blue 
colony producing vectors which doesn’t have inserts. Two white colonies and a blue 
colony (negative control) were picked from each plate in 30 µl of 1x PCR buffer. 
During that time, 5 ml of LB-broth prepared with amplcillin (5 µl/ml) in a 15 ml tube 
was inoculated with each clone separately, which was later used as a resource for 
plasmid DNA isolation. The bacteria in 1x PCR buffer were lysed by heating for 15 min 
at 95oC. The colonies were screened for the insert by performing a PCR with primers 
designed in the M13 promoter region of the vector. Twenty microlitre of reaction 
volume containing 10 µl of lysate, 1 µl of 10x buffer, 0.8 µl of dNTPs (10 pmol/µl),  
0.4 µl of each primers (forward: 5´-ttgtaaaacgacggccagt-3´, reverse: 5´-caggaaacagctatg 
acc-3´, concentration 10 pmol/µl) and 0.1 µl of Taq polymerase (5 units/µl) were 
amplified in the PTC-100 thermal cycler for 35 cycles of 95°C for 30 sec, 65°C for 30 
sec and 70°C for 30sec followed by another 5 minutes of final extension at 70°C. The 
products were electrophoresed in a 2% agarose gel. Clones were size fractionated on an 
agarose gel. Clones with an insert have higher molecular weight fragments than the blue 
clones.  
 
3.2.6.7 Sequencing 
 
The identity of inserts was confirmed by sequencing. Only colonies with right insert 
sequences were used in the next step. The protocol of this step was similar as described 
in 3.2.2.4. The sequencing was done using fluorescent labelled primers with the help of 
the SquiTherm EXCEL TM II DNA Sequencing Kit and LI-COR automated DNA 
sequencer. However, the primers used in this step were designed from SP6 (5’-
taaatccatgtgtatcttatg-3’) and T7 (5’-attatgctgctgagtgatatatcccgct-3’) promoter regions of 
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the pGEM-T vector and the templates were M13 PCR products from the previous step 
of cloning. 
 
3.2.6.8 Plasmid DNA isolation 
 
Plasmid DNA was isolated from the cultured E. coli cells using GenEluteTM Plasmid 
mini kit (Sigma, Germany). Five mililitre of bacterial culture was centrifuged at 12,000 
x g for 1 min and the supernatant was discarded. Cells were resuspended in 200 µl of 
resuspension solution. Two hundred mililitre of lysis solution was added to lyse the 
cells. The sample was then gently inverted for 8 to 10 times to mix them, until the 
mixture became clear and viscous. The mixture was incubated at room temperature for 
exactly 2 min. Precipitation of cell debris was done by adding 350 µl of neutralisation 
binding buffer into lysed cells, and mixed by inversion. The solution became cloudy and 
developed a flocculent white precipitant. The tubes were centrifuged for 10 min at 
≥12,000 x g. The clear supernatant was transferred to GenElute miniprep binding 
column and centrifuged at ≥12,000 x g for 1 min. The flow-through was carefully 
poured off from the tube and 750 µl of wash solution was added to the column, and then 
centrifuged at ≥12,000 x g for another 1 min. The flow-through was discarded and 
recentrifuged for 2 min without any additional washing buffer to remove excess ethanol. 
The column was transferred to a fresh collection tube, 50 µl of elution solution was 
added to the column followed by centrifugation at ≥12,000 x g for 1 min. Size and 
quality of plasmid DNA were checked by agarose gel electrophoresis. Quantity and 
quality were determined by spectrophotometer. The concentration of plasmid DNA was 
measured by the formula: 50 x absorbance at 260 nm x dilution factor. 
 
3.2.6.9 Plasmid serial dilutions 
 
The copy number per microlitre of plasmid DNA was calculated based on the size and 
concentration. Serial dilutions were then prepared from the concentration of 101 to 109 
copies/µl. The isolated plasmid DNA and serial dilutions were stored at -20°C. These 
DNA serial dilutions were used as template to generate the standard curve during real 
time PCR analysis.  
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3.2.7 Real time PCR 
 
The quantification of PRNP mRNA in oocytes, preimplantation embryos, 1-month-old 
foetuses as well as tissue samples with varying expression levels during semi-
quantitative PCR was done by real time quantitative PCR. PCR was conducted in an 
ABI Prism 7000 SDS instrument using SYBR® Green as a double-strand DNA-specific 
fluorescent dye. Quantitative analyses of cDNA from oocytes, embryos and 1-month-
old foetuses were performed in comparison to histone H2a (endogenous control) 
(Robert et al. 2002), and were run in separate wells whereas that of sample tissues were 
compared to 18S-rRNA. Standard curves were generated using serial dilutions of 
plasmid DNA (101 to 109 copies/µl). The PCR was performed in 20 µl reaction volume 
containing 2 µl of cDNA, 10 µl of 2x SYBR®Green JumpStartTM Taq ReadyMixTM with 
internal reference dye for quantitative PCR (Sigma), and optimal levels of forward and 
reverse primers. During each PCR reaction, samples from the same cDNA source were 
run in duplicate to control the reproducibility of results. Thermal cycle parameter were 
programmed at 95°C for 10 min followed by 45 cycles of denaturation at 95°C for 15 
sec and 60°C for 60 sec. After the end of the last cycle, a dissociation curve was 
generated by starting the fluorescence acquisition at 60°C and taking measurements 
every 7 sec interval until the temperature reached 95°C. Final quantitative analysis was 
done using the relative standard curve method as used in Tesfaye et al. (2004) and 
results were reported as the relative expression level compared to the calibrator cDNA 
after normalization of the transcript amount to the endogenous control.  
 
3.2.8 Statistical analysis 
 
PRNP mRNA expression by real time PCR was analysed based on the relative standard 
curve method. The relative expression data were analysed using the Statistical Analysis 
System (SAS) version 8.0 software package. Differences in mean values between 
developmental stages were tested using ANOVA followed by a multiple pair wise 
comparisons using t-test. Differences of p≤0.05 were considered to be significant. 
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3.2.9 PRNP mRNA localisation by fluorescent in situ hybridisation 
 
To localise the PRNP mRNA in ovaries and 1-month-old foetuses fluorescent in situ 
hybridisation was performed on 7 to 10 µm cryostat sections of snap frozen tissues.  
A non-radioactive probe with a reporter molecule digoxigenin (DIG) detected by the 
indirect method with the help of tyramide signal amplification (TSA) was applied in this 
experiment including six main steps of (I) generation of DIG-RNA probe, (II) tissue 
sectioning and fixation, (III) pre-treatment, (IV) hybridisation of probe to the target 
RNA, (V) posthybridisation washes and (VI) immunological detection of hybrids and 
visualisation. 
 
3.2.9.1 Generation of RNA probes 
 
The RNA probes used for in situ hybridisation (ISH) were generated and 
simultaneously labelled with DIG by in vitro transcription from cDNA template. The 
cDNA template required for the probe synthesis consisted of purified RT-PCR products 
from ovine brain RNA. Two different templates were required allowing the separate 
synthesis of antisense (as) and sense (s) probes. This was achieved by extending one of 
the two PRNP primers at its 5'-end by the sequence of the T7- or SP6-RNA-Polymerase 
promoter as shown in Table 6. The PCR with the oPRNP_for and SP6+oPRNP_rev 
primers led to the template for the antisense probe, and with T7+oPRNP_for and 
oPRNP_rev primers led to the template for the sense probe. Both antisense and sense 
PCRs were programmed at 94°C for 5 min, 40 cycles of 94°c for 30 sec, 60°C for 30 
sec, 72°C for 1 min followed by a final extension step at 72°C for 5 min. PCR products 
were assessed on a 2% agarose gel for quality measurement. The subsequent 
purification of the obtained PCR products provided optimal conditions for the 
transcription reaction by removing contaminations of primers, buffers and enzymes, 
using the QIAquick PCR purification kit (Qiagen) according to the manufacturer's 
protocol. The concentration was measured by the formula: 50 x absorbance at 260 nm x 
dilution factor. Finally, the PCR product was diluted to 100 ng/µl. 
The in vitro transcription of the DNA template to a single-stranded RNA probe in the 
presence of Dig labelled UTPs by the T7 and SP6 RNA polymerase was carried out 
according to the manufacturer's instructions of the DIG RNA labelling kit (Roche, 
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Germany). Ten microlitre of DNA template and 3 µl of DEPC-treated H2O were added 
in a 0.2 ml PCR tube and left at room temperature until the addition of the Master Mix. 
This Master mix was prepared at room temperature with 2 µl of 10x Dig NTP labelling 
mixture, 2 µl of 10x transcription buffer, 1 µl of RNase inhibitor and 2 µl of T7 or SP6 
RNA polymerase according to the promoter presented on the template. After gentle 
mixing and brief centrifugation, the mixture was incubated for 2 hours at 37°C. The 
reaction was stopped by adding 2 µl of 0.2 M EDTA (pH 8.0). The probe was purified 
to remove undesirable components of the transcription reaction by precipitation in 2 µl 
(0.1 volume) of 4 M LiCl and 50 µl (2.5 volume) of 100% ice cold ethanol for  
a minimum of 1 hour at -20°C. After centrifugation at ≥ 12,000 x g for 15 min at 4°C, 
the pellet was washed in 200 µl of 70% ice cold ethanol and centrifuged for another 10 
min. The pellet was finally air dried and dissolved in 20 µl of DEPC-treated H2O. The 
quality of RNA probes was checked by running 2 µl of RNA plus 2 µl of PAA loading 
buffer in a 1.5% FA gel. OD spectrometer values were taken to estimate the 
concentration of the probe by the formula: 40 x absorbance at 260 nm x dilution factor. 
A stock RNA probe was diluted in DEPC-treated H2O to a working concentration of 50 
ng/µl. Stock and working RNA probes were stored at -20°C. 
 
Table 6: Ovine PRNP primers for generating templates required for the probe 
synthesis. Forward primer (for) extended by the T7 promoter sequence and the standard 
reverse primer (rev) was used to generate a DNA template for ISH sense probe 
synthesis. While normal forward primer and reverse primer extended by SP6 promoter 
sequence were used to amplify DNA template for antisense probe synthesis. 
 
 Primer sequence Position within 
ref. sequence 
Accession 
number 
oPRNP_for 
SP6+oPRNP_rev 
5’-accaagctgaagcatctgtcttc-3’ 
5’-gatttaggtgacactatagaatggc 
ttactgggcttgttcc-3’ 
88 
 
- 
NM_001009481 
T7+oPRNP_for 
 
oPRNP_rev 
5’-gtaatacgactcactatagggacca 
agctgaagcatctgtcttc-3’ 
5’-tggcttactgggcttgttcc-3’ 
 
- 
484 
NM_001009481 
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3.2.9.2 Tissue sectioning and fixation 
 
The tissue samples stored at -80°C were transferred into the cryomicrotome for a 
minimum of 3 hours to allow the sample to warm to the chamber temperature of 
approximately -20°C. The specimen temperature (-20°C to -25°C) and speed of 
sectioning were pre-optimised for each kind of tissue. Sections of a thickness of 7 to 10 
µm were prepared at the optimal specimen temperature and a cutting angle of 2 to 3°, 
and were placed on room temperature warm SuperFrost® Plus slides (Menzel-Glaeser, 
Germany). The slides were then immediately placed on the quick freeze shelf (-45°C) 
for the section to refreeze and then kept in a precooled Hellendahl glass jar (Roth, 
Germany) within the cryomicrotome until fixation. All steps of in situ hybridisation 
were carried out in Hellendahl glass jars at room temperature unless noted otherwise. 
The sections were firstly fixed in 4% paraformaldehyde (PFA) for 15 min to inhibit 
cellular metabolism, deactivate lytic enzymes and endogenous RNases, and to conserve 
cellular morphology and nucleic acid integrity (Morel and Cavalier 2000). The sections 
were then washed twice with 1x PBS for 5 min each, and left in PBS until the next step 
of pretreatment. Once the sections were immersed in the fixation solution it was 
important to ensure that the sections never dried out during any subsequent steps until 
the staining was completed. 
 
3.2.9.3 Pretreatment of sections 
 
The main aim of the pretreatments is to make the target nucleic acid accessible to  
a probe. This may include modifying or destroying membrane and histone proteins, 
improving signal/background ratio as well as denaturing the target nucleic acid and the 
probe (Morel and Cavalier 2000). In this study, after tissue fixation, the sections were 
incubated in an ascending alcohol series of 50%, 70%, 90% and 100% ethanol for 5 min 
each (prepared fresh in DEPC-treated H2O), respectively. These steps were followed by 
a descending alcohol series of 90%, 70%, 50% ethanol for 5 min each, respectively 
(reused the solutions from the ascending series). The sections were washed in 1x PBS 
for 5 min, blocked in 0.6% H2O2 diluted in 1x PBS for 1 hour to quench an endogenous 
peroxidase activity and then washed twice with 1x PBS for 5 min each. 
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The acetylation reaction was performed to reduce background by transforming the 
reactive amine group (NH3+) of proteins into a substituted amine group (-NH-CO-CH3) 
(Morel and Cavalier 2000). For this purpose the sections were incubated in 0.1 M TEA 
buffer plus 0.25% acetic anhydride for 10 min. This solution was prepared just prior to 
usage due to the instability of acetic anhydride. Finally, the samples were equilibrated in 
2x SSC for 10 min. 
 
3.2.9.4 Hybridisation of probe to the target RNA 
 
The successful hybridisation is characterised by the formation of a stable and specific 
anti-sense probe complimentary to the target nucleic acid. Factors for a successful 
hybridisation are hybridisation buffer, hybridisation temperature, Na+ concentration, 
type and length of probe. The composition of the hybridisation buffer was based on the 
protocol of Thielen (2006). In this experiment, the sense probe served as negative 
control, since its sequence is identical to the target mRNA and does not attach to the 
target mRNA. A section hybridised with the sense probe was always prepared in 
parallel to each section hybridised with the antisense probe. In addition, different levels 
of probe amounts were used to optimise the hybridisation procedure. The probe was 
applied to the section as follows: after thawing the probe on ice, the RNA probes (sense 
or antisense) were added to the hybridisation buffer to yield a total volume of 100 
µl/section and the concentration of 500 ng/ml. This solution was mixed gently, exposed 
for 5 min at 80°C to denature the RNA probe and then immediately placed in ice to 
preserve the denatured structure. Following the final step of pretreatment, the section 
was placed horizontally in a humid chamber filled with DEPC-treated H2O, carefully 
overlaid with 100 µl of the hybridisation mixture and covered with a glass cover slip (24 
mm x 24 mm) before being incubated overnight at 52°C.  
 
3.2.9.5 Posthybridisation washes 
 
The aim of this step is to reduce background by removing unbounded and unspecifically 
bounded probe. This purpose can be achieved by controlling temperature, salinity of 
washing buffer, and RNase treatment. After the hybridisation step, the slips were rinsed 
off by flushing 2x SSC between slip and slide. The slides were washed twice in 2x SSC 
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at 45°C for 10 min each, twice in a mixture between formamide and 2x SSC (ratio 1:1) 
at 45°C for 10 and 20 min, respectively, and finally washed twice in 0.2x SSC on an 
orbital shaker at speed 100 rpm for 10 min at room temperature. The sections were then 
subjected to RNase digestion. Two different types of enzymes, RNase A and RNase T1 
were used. The sections were incubated for 30 min at 37°C in the combination of 5 µg 
of RNase A and 50 U of RNase T1 per ml of 2x SSC (Thielen 2006) followed by three 
times washing in 2x SSC on an orbital shaker at speed 100 rpm for 10 min at room 
temperature. 
 
3.2.9.6 Immunological detection 
 
TSA or tyramide signal amplification (fluorophore system) was integrated into the 
protocol. Tyramide is a phenolic compound that precipitates after oxidation. This 
technology uses HRP to catalyze the deposition of a fluorophore-labelled tyramide 
amplification reagent onto tissue sections surfaces. The reaction results in the deposition 
of numerous fluorophore labels immediately adjacent to the immobilised HRP enzyme 
(Figure 6).  
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Hybrid detection system including tyramide signal amplification 
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The TSA fluorophore system was carried out according to the manufacturer's 
instruction. Briefly, after posthybridisation washes (see 3.2.9.5) the sections were 
incubated in Tris-sodium (TN) buffer in a Hellendahl glass jar for 5 min. The slides 
were placed horizontal in a humidity chamber and incubated with TN blocking buffer 
(TNB) for 30 min. Next, the sections were incubated in peroxidase conjugated anti-DIG 
diluted 1:100 in TNB buffer (200 µl/section) for 1 hour and washed with three changes 
of TN buffer plus 0.05% Tween 20 (TNT) on an orbital shaker at speed 100 rpm for  
5 min each. Then, the fluorescent solution was added to the sections. The developing 
time was pre-optimised for each kind of tissue, 5 min for the brain, and 10 min for 
ovary and foetus. After another three times of washing in TNT buffer, the samples were 
finally counterstained in 0.5 µg/ml of propidiumiodide (diluted in TN buffer, 200 
µl/section) for 15 min followed by three times washing in TNT buffer on an orbital 
shaker at speed 100 rpm for 5 min each. A drop of Vecta shield mounting media was 
applied on the section; a glass cover slip was then placed over and fixed with nail 
polish. The staining of the sections was assessed by light microscopy (Microscope DM 
LB, Leica). 
 
3.2.10 Detection of PrPC expression by western blotting 
 
3.2.10.1 Protein extraction 
 
Protein was extracted using TRIZOLE reagent following the manufacturer's instruction. 
The tissue samples were taken out from storage at -80oC just before isolation. All 
centrifugation steps were performed at 4°C. Twenty miligramm of tissue was ground by 
using mortal and pestle and incubated with 0.5 ml of TRIZOL for 5 minutes at room 
temperature in a microcentrifuge tube. The clear homogenate was then mixed with 0.1 
ml of chloroform, vigorously shaked by hand for 15 sec and centrifuged at 12,000 x g 
for 15 min. A colourless upper aqueous phase was moved out and the DNA from the 
interphase and organic phase was precipitated by adding 150 µl of 100% ethanol. The 
mixture was mixed by inversion, allowed to stand for 2 to 3 min at room temperature 
and centrifuged at 2,000 x g for 5 min. The supernatant was transferred to a new 2.0 ml 
tube, 750 µl of isopropanal was then added and allowed to stand at room temperature 
for 10 min followed by centrifugation at 12,000 x g for 10 min. The protein pellet was 
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washed three times in 1 ml of 0.3 M guanidine hydrochloride/95% ethanol solution. 
During each wash, the sample was stored in wash buffer for 20 min at room temperature 
and centrifuged at 7,500 x g for 5 min. After the three washes, 1 ml of 100% ethanol 
was added and the mixture was allowed to stand for 20 min and then centrifuged at 
7,500 x g for another 5 min. Finally, the protein was dried under a vacuum for 5 min 
and dissolved in 200 µl of sample buffer containing 1% protease inhibitor cocktail 
followed by boiling for 5 min at 95°C and storing at -20°C.  
 
3.2.10.2 SDS-PAGE gel preparation  
 
SDS is an anionic detergent which denatures proteins by wrapping around the 
polypeptide backbone and confers a negative charge to the polypeptide in proportion to 
its length. An appropriate concentrated SDS-PAGE gel was used for the protein of 
interest. For the prion protein of ~ 30 kDa, a 15% acrylamide gel was prepared. Glass 
plates were cleaned thoroughly using normal detergent and distilled water. The 
sandwich glass plates were introduced into the support piece. It was confirmed that the 
lower border of the glass plates were well aligned and fixed on the rubber piece.  
The separation gel and stacking gel were prepared. The separation gel is used to 
separate proteins into their respective sizes allowing sharp bands to be seen, whereas the 
stacking gel organizes proteins before they enter the separating gel.  First, the separating 
gel was prepared, quickly mixed and poured in 3/4 volume of each sandwich plates and 
the remaining space (1/4 volume) was filled with isopropanol to ensure that no air 
bubbles would be formed at the surface of the gel during gel polymerization. The 
isopropanol was poured off after polymerization; the stacking gel was filled in the 
remaining space of the sandwich plates and, finally,  a 10 well comb was inserted on the 
top of the staking gel.  
 
3.2.10.3 SDS-PAGE gel electrophoresis 
 
One lit of 1x running buffer was prepared. After the gel was already polymerized, the 
comb was removed; two support pieces of the gel sandwiches were mounted with the 
U-shape rubber piece and then put into a chamber. The upper reservoir was filled with 
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running buffer and then 10 µl of each protein extract was added in the prepared well. 
The gel electrophoresis was run at 10 mA per one gel for 1.5 hours. 
 
3.2.10.4 Transferring proteins to the membrane  
 
Proteins were transferred into nitrocellulose transfer membrane using the Trans-Blot 
Semi-Dry transfer Cell. For each gel, one piece of transfer membrane and nine pieces of 
filter paper with the same size as the gel were prepared. Each of three pieces of the filter 
paper were wetting in anode buffer I, anode buffer II and cathode buffer, while the 
transfer membrane was soaked in distilled water. After the electrophoresis, the whole 
setup was dismounted, the stacking gel was discarded and the separation gel was moved 
and placed on the transfer membrane. Filter papers soaked in anode buffer I were placed 
on the anode plate of the blotter first followed by those paper soaked in anode buffer II. 
The transfer membrane and gel were removed from water and placed on top of filter 
paper stack followed by the paper in cathode buffer (Figure 7).  The cathode plate of the 
blotter was placed on top of transfer stack. The time of transfer was 1 hour using 100 
mA per each gel (1.75mA/cm2/h). After the transfer was completed, the blot membrane 
was washed with distilled water for 30 sec and subsequently stained with 0.2% ponceau 
S to evaluate the transfer quality. The membrane was then washed twice in PBST  
(10 min/time) on an orbital shaker.  
 
 
 
 
 
 
Figure 7: Diagram of transferring system 
 
3.2.10.5 Antibody incubation 
 
To block non-specific sites, the membrane was incubated in PBST containing 1% 
polyvinylpyrolidone (PVP, Sigma) for 1 hour at room temperature. The primary 
antibody was prepared by diluting PrP monoclonal antibody 12F10 in 0.1% PVP 
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Material and methods                                                                                                                                   57 
(dilution 1:250, Spibio, Montigny le Bretonneux, France). The membrane was 
incubated with the primary antibody overnight at 4°C or for 1 hour at room temperature 
followed by washing with six changes of PBST (10 min/time) at room temperature. 
Horseradish peroxidase goat anti-mouse (Jackson ImmunoResearch Laboratories, USA) 
diluted 1:15,000 in 0.1% PVP in PBST was then added to the membrane and incubated 
at room temperature for 1 hour. After incubation, the membrane was washed with six 
changes of PBST (10 min/time). All incubations, blockings and washing steps were 
done on an orbital shaker. 
 
3.2.10.6 Protein visualisation 
 
Immune complexes were detected using the ECL plus Western Blotting Detection 
System and visualized using Kodak BioMax XAR film. Briefly, the detection reagents 
were removed from storage at 2 to 8°C and allowed to equilibrate to room temperature. 
Solution A and B were mixed in a ratio 40:1. The final volume of detection reagent 
required was 2 ml per membrane. The membrane was taken out from the wash buffer 
and placed protein side up on a clean surface. The mixed detection reagent was applied 
on the membrane and incubated for 5 min at room temperature. For chemiluminescent 
detection, the membrane was placed on a fresh piece of saran wrap placed in an  
x-ray film cassette, wrapped up to gently remove any air bubbles. In the dark room,  
a sheet of autoradiography film was placed on top of the membrane and exposed for the 
appropriate time period of 1 to 5 min. 
 
3.2.11 Protein localisation by immunohistochemistry 
 
The cellular prion protein was localised in ovaries and 1-month-old foetuses using the 
immunohistochemical technique with the help of avidine-biotin complex to increase the 
signal of the staining. Primary and secondary antibodies used in this experiment were 
the same as used in western blot analysis. Immunohistochemical staining was 
performed on 5 to 7 µm cryostat sections of snap frozen tissues. Sample sections were 
placed on SuperFrost® plus slides and fixed in methanol and acetone for 10 and 1 min, 
respectively, at -20°C. The sections were air-dried for 15 min and washed with three 
changes of PBST. To quench an endogenous peroxidase activity, sections were 
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incubated in 0.3% H2O2 in methanol for 30 min, washed twice with PBS and then 
incubated in 1.5% goat normal serum in PBS for 1 hour. Endogenous biotin activity was 
blocked by incubating the sections in egg white (diluted 1:1 with ddH2O) for 15 min 
followed by washing with three changes of PBS. The PrP antibody 12F10 diluted 1:200 
in PBS was then applied on the sections and incubated for 1 hour at room temperature 
in an humidity chamber followed by three times washing with PBST. To detect the PrP 
antibody, sections were incubated in biotinylated goat anti-mouse IgG (dilution 1:100) 
for 30 min and washed with three changes of PBST. Avidine-biotinylated horseradish 
peroxidase was prepared 30 min prior to use following the manufacturer's instruction. 
This solution was added on the sections and allowed to stand for 30 min in the humidity 
chamber. The immune complexes were then visualised by incubating the samples with 
AEC (3-amino-9-ethylcarbazole) substrate for 30 min or until a desirable signal was 
obtained. The samples were counterstained with hematoxylin for 5 sec and immediately 
washed with several changes of deionised H2O. Finally, the samples were mounted 
using glycerol gelatine and covered with a cover glass slip and the staining was 
observed by light microscopy. 
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4 Results 
 
4.1 PRNP genotyping 
 
So far, many polymorphisms have been identified in the ovine PRNP gene. Correlations 
between those polymorphisms and the susceptibility to scrapie have been analysed 
resulting that the polymorphisms at codon 136, 154 and 171 within exon 3 of the PRNP 
gene are strongly linked to the variation in the phenotypic expression of scrapie. Based 
on the three polymorphisms twelve alleles can be derived; however, only five alleles 
and fifteen genotypes, which can be divided into five risk groups according to scrapie 
susceptibility, are commonly seen (Table 7 and 8).  
 
Table 7: The PRNP genotype distribution in sheep of the present study 
 
Risk group Genotype Number 
Genotype 
frequency (%) 
Risk group 
frequency (%) 
R1 ARR/ARR 74 22.84 22.84 
ARR/AHQ   4   1.23 
R2 
AHQ/AHQ   1   0.31 
  1.54 
ARR/ARQ 75 23.15 
ARR/ARH   1   0.31 
ARQ/AHQ 20   6.17 
R3 
ARH/AHQ   0   0.00 
29.63 
ARH/ARH   0   0.00 
ARQ/ARH   8   2.47 
ARQ/ARQ 74 22.84 
VRQ/ARR 19   5.86 
R4 
VRQ/AHQ   7   2.16 
33.33 
VRQ/ARQ 34 10.49 
VRQ/ARH   2   0.62 R5 
VRQ/VRQ   3   0.93 
12.04 
Unknown ARQ/ARK   2   0.62   0.62 
Total  324 100.0 100.0 
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Table 8: Allele frequencies of PRNP based on the polymorphisms at codons 136, 
154 and 171 within exon 3 
 
Allele Number Allele frequency (%) 
ARR 247 38.12 
ARQ 287 44.29 
ARH   11   1.70 
AHQ   33   5.09 
VRQ   68 10.49 
ARK     2   0.31 
 
 
The objectives of this study were to investigate PRNP expression during prenatal stages 
and to compare the expression of the gene between scrapie resistant animals and scrapie 
susceptible animals. So, this study was started at PRNP genotyping in sheep from some 
commercial farms and the Frankenforst experimental station of the University of Bonn. 
DNA from blood samples of 324 sheep of various breeds were sequenced using direct 
sequencing PCR. The results presented that the percentage of R1, R2, R3, R4 and R5 
sheep in this population were 22.8, 1.5, 29.6, 33.3 and 12.0%, respectively. The 
frequency of ARR/ARQ, ARR/ARR and ARQ/ARQ genotypes were 23.2%, 22.9% and 
22.9%, respectively, followed by VRQ/ARQ (10.5%), ARQ/AHQ (6.2%), VRQ/ARR 
(5.9%), ARQ/ARH (2.5%) and VRQ/AHQ (2.2%). The number of animals other 
genotypes was less than 1.5% per group. ARH/AHQ and ARH/ARH genotypes were 
not found in this population. Moreover, of all 324 animals, 2 animals could not be 
identified with their PRNP genotype (Table 7).  
Allele frequencies were calculated from the identified sheep showing that the frequency 
of ARR, ARQ, ARH, AHQ, VRQ and ARK alleles were 38.1, 44.3, 1.7, 5.1, 10.5 and 
3.1%, respectively, as shown in Table 8. 
After genotyping, R1 and R5 ewes were selected for further studies. The final number 
of ewes used in this experiment was 17; n=9 for R1 group and n=8 for R5 group. All the 
R1 ewes were the Black head breed, whereas seven ewes in R5 group were from the 
Bentheimer breed and one of them was from the Black head breed. PRNP sequencing 
was performed to confirm the genotypes in the selected ewes and their foetuses. Breeds 
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and PRNP genotypes of the sheep used in this experiment are shown in Table 9. The 
results showed that all the R1 ewes and foetuses used in this experiment were 
ARR/ARR genotype. Two PRNP genotypes of ARQ/VRQ and VRQ/VRQ genotypes 
were observed in the R5 group. All R5 ewes were ARQ/VRQ genotype whereas five R5 
foetuses carried the ARQ/VRQ and three foetuses carried the VRQ/VRQ genotype. The 
R1 ram used in this study was the Black head breed, which carried the ARR/ARR 
genotype, and the R5 ram was from the Bentheimer breed and carried the VRQ/VRQ 
genotype (data not shown).  
 
Table 9: Breed and PRNP genotypes of sheep used in this study 
 
Ewes Foetuses Month of 
pregnancy 
Breeds 
Genotype Group Genotype Group 
Black head ARR/ARR R1 ARR/ARR R1 
Black head ARR/ARR R1 ARR/ARR R1 
Black head ARR/ARR R1 ARR/ARR R1 
Bentheimer ARQ/VRQ R5 ARQ/VRQ R5 
1st 
Bentheimer ARQ/VRQ R5 ARQ/VRQ R5 
Black head ARR/ARR R1 ARR/ARR R1 
Black head ARR/ARR R1 ARR/ARR R1 
Bentheimer ARQ/VRQ R5 VRQ/VRQ R5 
 
2nd 
Bentheimer ARQ/VRQ R5 ARQ/VRQ R5 
Black head ARR/ARR R1 ARR/ARR R1 
Black head ARR/ARR R1 ARR/ARR R1 
Bentheimer ARQ/VRQ R5 ARQ/VRQ R5 
 
3rd 
Black head ARQ/VRQ R5 ARQ/VRQ R5 
Black head ARR/ARR R1 ARR/ARR R1 
Black head ARR/ARR R1 ARR/ARR R1 
Bentheimer ARQ/VRQ R5 VRQ/VRQ R5 
 
5th 
Bentheimer ARQ/VRQ R5 VRQ/VRQ R5 
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4.2 Expression of PRNP mRNA 
 
4.2.1 Expression of PRNP transcripts in ovine preimplantation embryos 
 
The gene expression between the two groups was detected and compared using 
quantitative real time PCR. This analysis was done in immature oocytes (n=2 per 
group), mature oocytes (n=3 per group), in vivo embryos at the morula stage (n=1 for 
R1 group and n=3 for R5 group) and in 1-month-old foetuses (n=2 per group). The 
results demonstrated that PRNP mRNA was detected in all stages.  
After adjusting the relative expression level using the level of R1 morula as the 
calibrator, the relative abundance of R1 immature oocytes, mature oocytes, morula-
stage embryos and 1-month-old foetuses were found to be 90.7, 5.9, 1.0 and 122.3, 
respectively. PRNP mRNA level in R1 mature oocyte was significantly lower than the 
levels in R1 immature oocyte and 1-month-old R1 foetuses (p≤0.05), whereas the 
expression levels of the gene compared between immature oocytes and 1-month-old 
stages were not significantly different (p>0.05).  
In the R5 group, the relative mRNA abundance was highest in 1-month-old foetuses, 
followed by immature oocytes, morula stage embryos and mature oocytes, respectively. 
The relative abundance levels of PRNP mRNA were 52.6, 1.1, 13.3 and 91.0 for R5 
immature ooytes, mature oocytes, morula-stage embryos and 1-month-old foetuses, 
respectively. The level of transcript abundance in R5 1-month-old foetuses was 
significantly higher than in the other stages (p≤0.05) of the same group. The transcript 
abundance in immature oocytes was also significantly higher than that of in vivo 
embryos and mature oocytes (p≤0.05); however, no significant difference between 
morula embryos and mature oocytes was observed (p>0.05).   
Compared within each stage between R1 and R5 groups, the results showed that the 
target gene expression in R1 group was higher than in the R5 group at immature oocytes 
and 1-month-old stages (p≤0.05), but no difference between these two groups was 
observed at mature oocytes stage (p>0.05, Figure 8). 
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Figure 8: Relative expression levels of PRNP mRNA in in vivo ovine immature oocytes 
(IMO), mature oocytes (MO), morula-stage embryos and 1-month-old foetuses.  The 
relative abundance of mRNA levels represents the amount of mRNA compared to the 
calibrator (R1 morula stage embryo) which is set to 1. Individual bars show the mean ± 
standard error (SE).  Values with different superscripts (A and B for R1 group, and a, b 
and c for R5 group) are significantly different within each group (p≤0.05), whereas * 
shows a significant difference between two groups at the same stage (p≤0.05). 
 
4.2.2 Expression of PRNP transcripts in ovine prenatal foetuses 
 
A semi-quantitative expression analysis of PRNP mRNA in various tissues of 2-, 3- and 
5-month-old foetuses of R1 and R5 groups showed that the PRNP mRNA was observed 
at all stages and in all tissues of both groups examined including brain, cotyledon, heart, 
intestine, kidney, liver, lung and muscle of 2-month-old foetuses (Figure 9), and 
cerebrum, cerebellum, medulla oblongata, cotyledon, spinal cord, heart, intestine, liver, 
lung, muscle and spleen of 3- and 5-month-old foetuses (Figure 10 and 11). In this 
study, 18S rRNA expression level was used as internal standard.  
The PRNP mRNA expression of each sample was identified as relative expression level 
compared to the level of 18S rRNA from the same cDNA source. The gene expression 
level was identified from the intensity of the PCR product band presented on agarose 
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gel under the UV light. The results showed that amplification of the 18S rRNA by RT-
PCR produces similar quantities of product for all tissues investigated.  
 
 
Figure 9: RT-PCR analysis of PRNP and 18S mRNA in various tissues of  
2-month-old R1 and R5 foetuses. The negative control reactions were done with no 
template DNA   
 
In 2-month-old foetuses, PRNP bands were strongest in brain tissue of both R1 and R5 
foetuses, resulting that PRNP mRNA abundance was highest in the brain tissue of the 
foetuses. The PRNP levels were moderate in heart, intestine and lung, and were low in 
kidney and liver of the two groups. Variation of the gene transcripts in cotyledons and 
muscle, when compared between two independent samples of each group, were 
observed. In both R1 and R5 groups, one cotyledon sample showed similar expression 
level as those of the brain (high level), whereas the other one showed similar level as 
kidney and liver (low level). In muscle tissue, one sample represent similar expression 
level as the levels in heart, intestine and lung (moderate level) while the other one 
presented low expression level as kidney and liver (Figure 9). 
PRNP transcripts were observed in all R1 and R5 foetal tissues studied at the 3rd and 5th 
month after insemination as well. The results of RT-PCR are presented in Figure 10 and 
Figure 11. Comparison between various tissues at the 3rd month (B) of R1 foetuses 
shows that the gene expression levels were high in cerebrum, cerebellum, medulla 
oblongata, cotyledon and spinal cord. The level(s) were moderate in intestine, lung, 
muscle and spleen, and was low in liver. A low expression level of this transcript was 
also found in the heart of an individual R1 foetus at this stage, while the level of the 
other foetus was moderate. At the 5th month after insemination (C), the levels of the 
gene transcripts could be divided into two groups. High expression levels were found in 
Results                                                                                                                                                          65                                                                                          
 
cerebrum, cerebellum, medulla oblongata, cotyledon and spinal cord, while the 
moderate expression levels were detected in the rest of the tissues. Comparing within 
each tissue between these stages, the gene abundance levels in liver and spleen at the 5th 
month were higher than those levels at the 3rd month. Whereas it seems to be unchanged 
through the prenatal stage in the rest of the tissues (Figure 10) 
 
 
 
Figure 10: RT-PCR analysis of PRNP and 18S mRNA in 1-month-old R1 foetuses 
(A) and in various tissues of 3- (B) and 5-month-old (C) R1 foetuses. The negative 
control reactions were done with no template DNA   
 
In 3-month-old R5 foetuses, the gene expression levels of various tissues can be 
catagorised into 3 groups; high expression levels were found in cerebrum, cerebellum, 
medulla oblongata, cotyledon and spinal cord, while the levels in heart, intestine, lung 
and muscle were moderate, and in liver and spleen were low. At the 5th month, the 
results showed the same trend as those at the 3rd month. However, comparison within 
each tissue between two stages of foetuses demonstrates that PRNP expression levels in 
cerebrum at the 5th month were lower than that of the 3rd month, whereas the level in the 
medulla oblongata at the 5th month was higher than the level at the 3rd month (Figure 
11) 
Comparisons within each tissue and each stage between the two groups indicates that 
the PRNP mRNA levels in the heart of R1 foetuses were lower than that of R5 foetuses 
at the 3rd month while the levels at the 5th month were higher in R1 cerebrum and liver, 
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and lower in R1 medulla oblongata as compared with those in R5 foetuses (Figure 10 
and Figure 11)  
 
 
 
Figure 11: RT-PCR analysis of PRNP and 18S mRNA in 1-month-old R5 foetuses 
(A) and in various tissues of 3- (B) and 5-month-old (C) R5 foetuses. The negative 
control reactions were done without template DNA   
 
Following to the results of RT-PCR that showed differences of the gene abundance in 
heart, liver and spleen of R1 foetuses, and in cerebrum, medulla oblongata, and spleen 
of R5 foetuses, quantitative real time RT-PCR was performed to define the amount of 
gene transcripts in cerebrum, medulla oblongata, heart, liver and spleen of both groups 
using the level of 18S rRNA as an internal standard. The relative levels of PRNP 
mRNA of each independent sample are shown in Table 10, while mean and standard 
error of each group are shown in Figure 12. 
In 3-month-old R1 foetuses, the relative abundance of the gene transcript was highest in 
cerebrum followed by medulla oblongata, spleen, heart and liver, respectively. The 
levels were 47.9, 41.4, 4.3, 2.2 and 5.5 for 3-month-old R1 cerebrum, medulla 
oblongata, heart, liver and spleen samples, respectively. In 5-month-old R1 foetuses, the 
levels of PRNP transcript in the tissues mentioned above were 35.1, 50.1, 7.0, 8.0 and 
9.4, respectively. The levels in cerebrum and medulla oblongata at this stage were also 
higher than those of the rest of the tissues.  
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Table 10: Relative abundance of PRNP mRNA (x10-6) in foetal cerebrum, medulla 
oblongata, heart, liver, and spleen of each individual at the 3rd and 5th month of 
pregnancy 
 
Relative abundance of PRNP mRNA 
Tissue Stage Group 
Animal 1 Animal 2 
R1 57.33 38.54 
3 month 
R5 41.54 25.58 
R1 39.00 31.18 
Cerebrum 
5 month 
R5 20.88 28.32 
R1 48.27 34.45 
3 month 
R5 22.28 41.87 
R1 81.46 18.77 
Medulla 
oblongata 
5 month 
R5 78.48 56.04 
R1   3.00   5.59 
3 month 
R5   6.05   8.45 
R1   8.40   5.53 
Heart 
 
5 month 
R5   5.79   9.17 
R1   2.08   2.22 
3 month 
R5   2.24   2.45 
R1   4.66 11.30 
Liver 
5 month 
R5   3.38   1.67 
R1   6.40   4.62 
3 month 
R5   3.20   5.37 
R1 10.33   8.55 
Spleen 
 
5 month 
R5 10.41   4.98 
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Figure 12: Relative expression levels of PRNP mRNA (x10-6) in foetal tissues of 
scrapie resistant (R1) and susceptible (R5) groups at the 3rd and 5th month of pregnancy. 
Individual bars show the mean ± SE (n=2 per group).   
 
In R5 foetuses, the relative abundance of the PRNP gene was similar to those of the R1 
foetuses. The gene expression levels in medulla oblongata and cerebrum were higher 
than those in heart, liver and spleen. At the 3rd month of pregnancy, the levels of PRNP 
transcript in the tissues mentioned above were 33.6, 32.1, 7.3, 2.4 and 4.3, respectively. 
At the 5th month, the levels in R5 cerebrum, medulla oblongata, heart, liver and spleen 
were found to be 24.6, 67.3, 7.5, 2.5 and 7.7, respectively.  
Comparing between R1 and R5 groups within each tissue of each stage, real time RT-
PCR analyses resulted in higher expression level of PRNP gene in R1 cerebrum and R1 
spleen at both stages of 3 and 5 months of age compared to R5 cerebrum and R5 spleen, 
respectively. The levels in the heart of R1 foetuses were lower than those of R5 foetuses 
at both stages. In medulla oblongata, the expression level of R1 foetuses at the 3rd 
month was higher than the level of R5 foetuses, but at the 5th month, the level of R1 
foetuses was lower than the level of R5 foetuses. These results are opposite to the 
results in liver that showed lower expression level of the gene in R1 foetuses at the 3rd 
month and higher expression level at the 5th month compared to the levels of R5 
foetuses.  
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Comparison between the different stages within the same group demonstrated that the 
relative expression levels of PRNP mRNA in cerebrum at the 3rd month of both R1 and 
R5 groups were higher than those at the 5th month. The levels in the rest of the tissues 
were lower at the 3rd month compared to levels at the 5th month.  
 
4.2.3 Expression of PRNP transcripts in reproductive organs of ewes 
 
The results of semi-quantitative RT-PCR in ovine reproductive tissues revealed the 
presence of the gene transcript in ovary, oviduct, endometrium, myometrium and 
caruncle of R1 and R5 ewes at all stages (Figure 13 and Figure 14). In this experiment, 
the expression patterns of the two groups were likely similar. Compared within each 
group, the highest expression level was found in caruncle tissue at all stages 
investigated, whereas the relative expression levels of PRNP mRNA in ovary, oviduct, 
endometrium and myometrium were lower and not different from each other. However, 
the levels of the gene mRNA abundance in R1 caruncle seems to be unchanged 
throughout the pregnancy period while it was increased from the 1st month to the 3rd 
month, and decreased from the 3rd to the 5th month in R5 caruncle. When compared 
between R1 and R5 groups, the results showed that the expression level of PRNP 
transcript in caruncle tissue of R1 ewes was higher than that of R5 ewes at the 1st month 
of pregnancy, while it was lower at the 3rd month. Moreover, at the 1st month, one of the 
sheep in R1 group showed higher expression level in endometrium compared to the R5 
group, while the other one was similar to the levels of the R5 group. The relative 
abundance of the gene transcript in other tissues was not different compared between 
R1 and R5 group.  
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Figure 13: RT-PCR analysis of PRNP and 18S mRNA in reproductive tissues of 
scrapie resistant ewes at the 1st (A) , 3rd (B) and 5th (C) month of pregnancy. The 
negative control reactions were done with no template DNA   
 
 
 
 
Figure 14: RT-PCR analysis of PRNP and 18S mRNA in reproductive tissues of 
high susceptible ewes at the 1st (A), 3rd (B) and 5th (C) month of pregnancy. The 
negative control reactions were done with no template DNA   
 
Real time PCR was carried out to quantify the amount of PRNP transcripts in 
endometrium of ewes at the 1st month of pregnancy, and in caruncle at the 1st, 3rd and 5th 
month of pregnancy with three replications using 18S rRNA as an internal standard. 
The results of real time PCR supported the results obtained by RT-PCR as shown in 
Figure 15. Relative PRNP expression levels were 25.5 and 5.4 for R1 endometrium, and 
10.2 and 13.3 for R5 endometrium. The levels of R1 caruncle at the 1st, 3rd and 5th 
month were 28.5 and 67.7, 35.8 and 48.1, and 24.0 and 28.6, respectively. While the 
levels of R5 caruncle were 16.7 and 17.8, 47.4 and 42.3, and 16.3 and 41.1 at the 1st, 3rd 
and 5th month of pregnancy, respectively. Mean and standard error of the relative 
abundance of PRNP transcript in R1 and R5 endometrium at the 1st month of pregnancy 
were 15.5 ± 10.0 and 11.8 ± 1.5, respectively. The levels in caruncle tissue of R1 and 
R5 ewes were 48.1 ± 19.6 and 17.2 ± 0.6, 42.0 ± 6.1 and 44.9 ± 2.6, 26.3 ± 2.3 and 28.7 
± 12.4 at the 1st, 3rd and 5th month, respectively. 
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Figure 15: Relative expression levels of PRNP mRNA (x10-6) in endometrium and 
caruncle of resistant (R1) and high susceptible (R5) ewes (n=2 per group). 
 
 
4.3 Localisation of PRNP mRNA 
 
The results of PRNP mRNA expression analyses showed the presence of the gene 
transcripts in the total RNA extracted from the whole foetuses at 1 month of age and the 
ovaries of ewes. However, ovaries comprise of many types of cells which are involved 
in folliculogenesis such as follicular cells, granulosa cells, theca interna, theca externa, 
cortical stroma or corpus luteum. So, in this study, fluorescent in situ hybridisation was 
used as a tool for localisation of the gene mRNA in ovary tissue and in 1-month-old 
foetuses of R1 and R5 groups. RNA probes used in this study were digoxigenin 
labelled. After hybridisation, the hybrids were detected by anti-digoxigenin-POD 
followed by the fluorescein TSA reagent. The nucleus of the cell was labelled with 
propidiumiodide. Under the fluorescent microscope the fluorescein signals were shown 
in green while propidiumiodide was shown in red.   
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4.3.1 Localisation of PRNP mRNA in 1-month-old foetuses 
 
PRNP transcripts were detected in various organs of 1-month-old R1 and R5 foetuses of 
sheep. The fluorescent signals of PRNP mRNA hybrids were detected in the brain 
(Figure 16A and B), vertebral column (Figure 16D and E), heart (Figure 16G and H), 
liver (Figure 16J and K) and kidney (Figure 16M and N) of R1 and R5 foetuses, 
respectively. Signals were not found in the negative control sections of heart (Figure 
16I), liver (Figure 16L) and kidney (Figure 16O), which were hybridised with the sense 
probe. Weak signals were detected in the control sections of the brain (Figure 16C) and 
vertebral column (Figure 16F); however, the samples hybridised with antisense probe 
displayed a higher signal above these background.  
  
4.3.2 Localisation of PRNP mRNA in adult ovaries 
 
In situ hybridisation of the PRNP mRNA was also detectable in the ovary of both R1 
and R5 groups. Signals were detected in granulosa cells and theca cells (Figure 17A, E), 
ovarian cortex (Figure 17B, F), ovarian medulla (Figure 17C, G) and corpus lutuem 
(Figure 17D, H) of R1 and R5 ovaries, respectively. Signals were not found in the 
control sections hybridised with sense probe as shown in Figure 17I, J, K and M. 
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Figure 16: Fluorescent in situ hybridisation of PRNP mRNA with DIG labelled 
RNA antisense (left and middle column) and sense (right column) probes in 1-month-
old R1 (A, D, G, J and M) and R5 (B, E, H, K and N) ovine foetuses. PRNP transcripts, 
which are shown in green or point with blue arrow, were detected in brain (A and B), 
vertebral column (D and E), heart (G and H), liver (J and K) and kidney (M and N) of 
the foetuses compared to the control sections of each organ which are shown in the 
same line 
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Figure 17: Fluorescent in situ hybridisation of PRNP mRNA with DIG labelled RNA antisense (A-H) and sense (I-L) probes in R1 (A-D) 
and R5 (E-H) ovaries collected at the 1st month of pregnancy.  PRNP transcripts, which are shown in green, were found in oocyte, granulosa 
cells and theca cells (A and E) as well as in ovarian cortex (B and F), ovarian medulla (C and G) and corpus luteum (D and H) compared to 
the control sections of each which are shown in the same column  
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4.4 Expression of PrPC, western blot analysis 
 
In order to study the PrPC expression in reproductive tissues of ewes and various tissues 
of their foetuses, western blot analysis was performed to detect PrPC in the samples and 
to compare the expression level of the protein between samples. According to the 
results of mRNA expression analyses, female reproductive tissues obtained from ewes 
at the 1st month of pregnancy, the whole foetuses at the 1st month and the foetal tissues 
at the 2nd month of embryogenesis were used to identify the location of the PrPC in each 
tissue, and to compare the protein expression between the two groups.  
 
4.4.1 Expression of PrPC in ovine prenatal foetuses 
 
To study the expression of PrPC in the ovine prenatal foetuses, western blot analysis was 
performed. The proteins extracted from whole prenatal foetuses at 1 month of age and 
from separated single organs of the foetuses at 2 months of age were used to detect and 
compare the expression level of the protein between R1 and R5 groups. The results 
showed that the immunoreactive bands corresponding to the PrPC were detected in all 
samples examined. The expression patterns were not different between the two groups. 
The intensity of the PrPC band at the expected molecular weight of ~33 kDa was 
strongest in liver compared to the other tissues. The level of the protein in brain was 
high when compared to the levels in heart, intestine, kidney, lung and muscle. The 
protein expression levels in heart, intestine, lung and muscle were quiet similar. In this 
study, PrPC levels detected in cotyledon samples of both groups were very low, even 
when a double volume of protein extract from this tissue was loaded (Figure 18). 
 
4.4.2 Expression of PrPC in reproductive organs of ewes 
 
PrPC of ~33 kDa could be detected in all female reproductive organs investigated 
including ovary, oviduct, endometrium, myometrium and caruncle. The prion protein 
expression patterns of the two risk groups were similar. The intensity of the PrPC bands 
in endometrium, myometrium and caruncle tissue was higher compared to those of 
ovary and oviduct tissue. Moreover, the protein levels in ovary, endometrium, 
myometrium and caruncle tissue were not different when compared in each tissue 
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between R1 and R5 ewes, but it was higher in R5 oviduct than that of R1 oviduct 
(Figure 19). 
 
 
Figure 18: Representative western blot analysis of PrPC in ovine foetal tissues 
showed the immunoreactive band corresponding to the PrPC in 1-month-old foetuses 
and various tissues of 2-month-old foetuses of both R1 and R5 groups. Negative control 
membrane was devoid of the PrP MAb incubation 
 
 
 
Figure 19: Representative western blot analysis of PrPC in ovine reproductive 
tissues showed the immunoreactive band corresponding to PrPC in ovary, oviduct, 
endometrium, myometrium and caruncle of resistant (R1) and high susceptible (R5) 
ewes 
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4.5 Localisation of PrPC 
 
As it has been done for PRNP mRNA localisation immunohistochemistry was done to 
localise PrPC in ovary tissue and in 1-month-old foetuses of both groups. The technique 
was optimised firstly using various regions of the brain including cerebrum, cerebellum 
and medulla oblongata, which served as positive control. In this study, the antigen-
antibody binding was visualised using HRP-AEC substrate and the sample was 
counterstained using haematoxylin. HRP-AEC substrate produced red-rose colour 
during the enzymatic reaction while haematoxylin produced blue colour on the nucleus 
of the cell. As a result, PrPC was detected in every region of the brain examined (Figure 
20) with intense staining in the interface between the white and grey matter of cerebrum 
and cerebellum of R1 (Figure 20 A, D) and R5 (Figure 20 B, E) groups. After 
optimisation, immunohistochemistry was performed in adult ovaries and 1-month-old 
foetuses, while adult brain was stained in parallel as positive controls. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Immunohistochemistry of the prion protein with PrP MAb 12F10 in 
adult brain of sheep using HRP-AEC substrate which produces the red-rose colour 
during the emzymatic reaction as a chromogen. PrPC (shown in red) was detected in the 
gray matter of cerebrum, interface between the white matter and the gray matter of 
cerebellum and also in the medulla oblongata. Control sections were devoid of specific 
staining with the PrP MAb (data not shown)   
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Figure 21: Immunohistochemistry of the prion protein with PrP MAb 12F10 in 
ovine 1-month-old R1 (A, B and C) and R5 (D, E and F) foetuses using HRP-AEC 
substrate which produces the red-rose colour during the emzymatic reaction as  
a chromogen. PrPC (shown in red) was detected in brain (A and D), heart (B and E) and 
kidney (C and F). Immunostaining of the PrPC was not found in liver and dermatome 
(E). Control sections were devoid of specific staining with the PrP MAb (G, H and I) 
 
4.5.1 Localisation of PrPC in 1-month-old foetuses 
 
Immunohistochemistry was done in snap-frozen sections of 1-month-old R1 and R5 
foetuses. The results presented PrPC in brain (Figure 21A, D), heart (Figure 21B, E) and 
kidney (Figure 21C, F) of R1 and R5 foetuses, respectively, compared to the control 
sections that were devoid of specific staining with the PrP MAb of brain (Figure 21G), 
heart (Figure 21H) and kidney (Figure 21I). Under the light microscope, the staining 
was detected around the nucleus of the cells. In this experiment, the intensity of the 
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PrPC staining was not different between R1 and R5 foetuses. The staining was found to 
be more intense in the heart of the foetuses than in kidney and even in the brain. In 
addition, PrPC was not detectable in the other organs of the foetuses such as eye (data 
not shown), liver or dermatome (Figure 21E). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Immunohistochemical localisation of PrPC in ovine ovaries (black 
arrow). Strong staining was found in ovarien cortex (A and D) and ovarian medulla (B 
and E) of R1 and R5 ewes, respectively. PrPC was not detected in the oocyte, granulosa 
cells and theca cells of R5 animal (G) and in corpus luteum (C and F) of R1 and R5 
ewes, respectively. Ovine brain was stained in parallel as positive control for PrPC 
immunostaining (H). Control sections were devoid of specific staining with the PrP 
MAb (I) 
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4.5.2 Localisation of PrPC in adult ovaries 
 
Immunohistochemical localisation was performed in the ovary of both R1 and R5 
groups. The results in R1 and R5 ovaries were not different; immunostaining of PrPC 
which is shown in red under the light microscope was detectable in cortex (Figure 22A, 
D) and medulla (Figure 22B, E) of R1 and R5 ovaries, respectively. The staining was 
not seen in corpus luteum (Figure 22C, F) of both groups, neither in oocyte, granulosa 
and theca cells (Figure 22G) of R5 ovary in this study. Comparison of the expression 
level of the protein between ovarian cortex and ovarian medulla demonstrates the higher 
immune complexes signal in ovarian medulla than that in cortex. 
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5 Discussion 
 
At the present, the precise molecular function of prion protein gene is unclear. This 
study was carried on the basis that the timing and distribution of prion protein mRNA 
and the protein expression knowledge may lead to better understanding of its function. 
Semi-quantitative RT-PCR, quantitative real-time PCR and fluorescent in situ 
hybridisation were used to characterise prion protein gene (PRNP) expression and 
location, while immunohistochemistry was used to investigate the location of the 
protein in organs. According to previous studies showing that polymorphisms at codons 
136, 154 and 171 of the ovine PRNP associate to the prion disease susceptibility. 
Animals carrying resistant (R1) or high susceptible (R5) genotypes were used. 
 
5.1 Genotype and allele frequencies of the PRNP 
 
The results of this study showed the genotype and allele frequencies for different amino 
acids at positions of 136, 154 and 171 of the PRNP in various breeds of sheep. At codon 
136 alanine (A) and valine (V) were observed, at codon 154 arginine (R) and histidine 
(H) were observed, and at codon 171 glutamine (Q), arginine and histidine were 
commonly detected; two animals from a commercial flock carried lysine (K) at the 
codon 171. The genotype of these two animals was ARQ/ARK which is rare;  
a classification in one of the risk groups is not possible. As it has been the case for the 
other sheep breeds, not all possible allelic and genotypic variants were observed. In this 
study, six allelic variants and thirteen genotypes were shown. Similar to Acutis et al. 
(2004) and Gombojav et al. (2003), the allelic variant ARK was observed besides the 
other five common alleles of ARR, ARQ, ARH, AHQ and VRQ in Italian Biellese 
breed rams and Mongolian sheep; twenty-one and eleven genotypes were found in those 
studies, respectively. From the previous studies of Acin et al. (2004) and Tranulis et al. 
(1999), five common allelic variants were seen in native healthy Spanish and 
Norwegian sheep; nevertheless, only the ARQ, AHQ and VRQ alleles and six 
genotypes were shown in Icelandic sheep (Thorgeirsdottir et al. 1999) (Table 11 and 
Table 12.) 
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Table 11: Frequencies of PRNP genotypes in sheep of the present study and in 
Icelandic, Norwegian, Italian, Mongolian and Spanish sheep  
 
Risk 
group 
PRNP 
genotype 
Present 
study 
Icelandic 
sheep1 
Norwegian 
sheep2 
Italian  
ram3 
Mongolian 
sheep4 
Spanish 
sheep5 
R1 ARR/ARR 22.84 0.0 12.5 1.4 1.8 2.4 
ARR/AHQ 1.2 0.0 6.3 0.7 0.4 1.4 
R2 
AHQ/AHQ 0.3 0.2 0.8 0.2 0.0 0.0 
ARR/ARQ 23.2 0.0 31.7 11.4 18.8 23.2 
ARR/ARH 0.3 0.0 2.1 0.5 0.0 3.1 
ARQ/AHQ 6.2 6.6 10.4 5.5 0.4 3.7 
R3 
ARH/AHQ 0.0 0.0 0.0 0.4 0.4 0.0 
ARH/ARH 0.0 0.0 0.0 0.2 1.8 0.4 
ARQ/ARH 2.5 0.0 3.8 5.7 8.1 6.6 
ARQ/ARQ 22.8 75.9 16.7 56.3 66.4 50.4 
VRQ/ARR 5.9 0.0 4.6 1.2 0.4 1.5 
R4 
VRQ/AHQ 2.2 0.7 1.3 0.3 0.0 0.2 
VRQ/ARQ 10.5 16.0 8.3 9.9 1.1 5.7 
VRQ/ARH 0.6 0.0 0.0 0.7 0.0 1.0 R5 
VRQ/VRQ 0.9 0.7 1.7 0.7 0.0 0.5 
ARQ/ARK 0.6 0.0 0.0 3.8 0.0 0.0 
ARR/ARK 0.0 0.0 0.0 0.1 0.0 0.0 
ARH/ARK 0.0 0.0 0.0 0.3 0.0 0.0 
AHQ/ARK 0.0 0.0 0.0 0.3 0.0 0.0 
VRQ/ARK 0.0 0.0 0.0 0.2 0.0 0.0 
NC 
ARK/ARK 0.0 0.0 0.0 0.2 0.4 0.0 
Total  100.0 100.0 100.0 100.0 100.0 100.0 
Adapted from: 1/ Thorgeirsdottir et al. (1999), 2/ Tranulis et al. (1999), 3/ Acutis et al. 
(2004), 4/ Gombojav et al. (2003), 5/ Acin et al. (2004) 
NC: Not classified 
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Table 12: Frequencies of PRNP alleles in sheep of the present study and in 
Icelandic, Norwegian, Italian, Mongolian and Spanish sheep 
 
PRNP allele 
Present 
study 
Icelandic 
sheep1 
Norwegian 
sheep2 
Italian  
ram3 
Mongolian 
sheep4 
Spanish 
sheep5 
ARR 38.1 0.0 34.8 8.3 11.6 17.1 
ARQ 44.3 87.2 43.8 74.4 80.6 69.6 
ARH 1.7 0.0 2.9 3.8 6.1 5.6 
AHQ 5.1 3.8 9.8 4.1 0.6 3.6 
VRQ 10.5 9.0 8.8 6.8 0.7 4.2 
ARK 0.3 0.0 0.0 2.5 0.4 0.0 
Total 100.0 100.0 100.0 100.0 100.0 100.0 
Adapted from: 1/ Thorgeirsdottir et al. (1999), 2/ Tranulis et al. (1999), 3/ Acutis et al. 
(2004), 4/ Gombojav et al. (2003), 5/ Acin et al. (2004) 
 
 The most frequent combination of the three codons in this experiment was ARQ 
(44.0%), and the high frequent genotypes of more than 20% were ARR/ARQ, 
ARQ/ARQ and ARR/ARR (23.2, 22.9 and 22.9%, respectively). The animals with 
ARR/ARQ or ARQ/ARQ are moderately susceptible to scrapie, while the animals with 
ARR/ARR seem to be resistant to scrapie, as was shown by many studies with naturally 
or experimentally infected sheep (Belt et al. 1995, Goldmann et al. 1994, O'Doherty  
et al. 2002, O'Rourke et al. 1997, Thorgeirsdottir et al. 1999). Fortunately, while the 
allelic variant ARR, which is associated to resistance to scrapie, was represented at  
a frequency of 38.0%, the frequency of the allelic variant VRQ, which is known to carry 
a high susceptibility, was represented at  11.0% in the examined group of sheep. These 
results are in agreement with several investigations, which showed the highest 
frequency in ARQ allele followed by the ARR allele in Icelandic (Thorgeirsdottir et al. 
1999), Norwegian (Tranulis et al. 1999), Italian (Acutis et al. 2004), Mongolian 
(Gombojav et al. 2003) and Spanish sheep (Acin et al. 2004). The frequency of ARQ 
allele ranges from 43.8 to 87.2%, and that of ARR, ARH, AHQ and VRQ alleles range 
from 0.0 to 38.1, 0.0 to 6.1, 0.6 to 9.8 and 0.7 to 10.5%, respectively (Table 12).  
The PRNP genotype frequencies in this study were also in agreement with observations 
made in four healthy major breeds of sheep in Norway that showed the highest 
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frequency in ARR/ARQ genotype followed by ARQ/ARQ genotype. In contrast, the 
ARQ/ARQ genotype was more frequent than the ARR/ARQ genotype in Icelandic 
sheep (scrapie-free regions and scrapie regions), Italian Biellese ram, healthy Spanish 
and Mongolian sheep (Acin et al. 2004, Acutis et al. 2004, Gombojav et al. 2003, 
Thorgeirsdottir et al. 1999, Tranulis et al. 1999) (Table 11). 
The genetic data on the PRNP polymorphisms offer the possibility of controlling natural 
scrapie in sheep populations by selecting genotypes carrying scrapie resistant alleles or 
either by eliminating the PRNP genotypes carrying high susceptible alleles in breeding 
animals. Breeding programmes for animals carrying genotypes that determine resistance 
and the elimination of animals with the VRQ allele are already underway in many 
European (EU) countries. An increase in ARR/ARR genotype frequency was shown in 
ovine animals from European Commission member states (without United Kingdom, 
UK) during the period of 2002 to 2005. ARR/ARR genotype frequencies in 2002, 2004 
and 2005 were 14.0, 18.0 and 21.0%, respectively (European Commission 2003, 2005, 
2006). 
In this experiment, sheep were grouped based on the classification system mentioned in 
Erhardt et al. (2002). This classification system is different from the NSP system used in 
the UK as shown in Table 13 (European Commission 2004). 
 
Table 13: The PRNP genotypes and risk groups in accordance with the NSP 
classification system used in the United Kingdom 
 
Risk group Genotype 
NSP1 ARR/ARR 
NSP2 ARR/ARQ, ARR/ARH, ARR/AHQ 
NSP3 (ARQ/ARQ) ARQ/ARQ 
NSP3 (others) AHQ/AHQ, ARH/ARH, ARQ/ARH, ARQ/AHQ, ARH/AHQ  
NSP4 ARR/VRQ 
NSP5 VRQ/ARQ, VRQ/ARH, VRQ/AHQ, VRQ/VRQ 
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Table 14: PRNP genotypes frequencies in the examined group of sheep in 
accordance with the NSP classification system used in the United Kingdom 
 
Risk group Genotype 
Number of 
animals 
Genotype 
frequency (%) 
Risk group (%) 
NSP1 ARR/ARR 74 22.84 22.84 
ARR/ARQ 75 23.15 
ARR/ARH 1 0.31 NSP2 
ARR/AHQ 4 1.23 
24.69 
NSP3 (ARQ/ARQ) ARQ/ARQ 74 22.84 22.84 
AHQ/AHQ 1 0.31 
ARH/ARH 0 0.00 
ARQ/ARH 8 2.47 
ARH/AHQ 0 0.00 
NSP3 others 
ARQ/AHQ 20 6.17 
8.95 
NSP4 VRQ/ARR 19 5.86 5.86 
VRQ/ARQ 34 10.49 
VRQ/ARH 2 0.62 
VRQ/AHQ 7 2.16 
NSP5 
VRQ/VRQ 3 0.93 
14.20 
Unknown ARQ/ARK 2 0.62 0.62 
Total  324 100.00 100.00 
 
The European Commission (2006) reported that, in 2005, the frequencies of NSP1, 
NSP2, NSP3 (ARQ/ARQ), NSP3 (others), NSP4 and NSP5 risk groups in 190,577 
sheep from EU member states were 21.0, 37.0, 26.0, 9.0, 2.0 and 4.0%, respectively. 
After reclassification of  PRNP genotypes in the examined sheep according to the NSP 
system, the results showed that the frequencies in our population were 22.8, 24.7, 22.8, 
9.0, 5.9 and 14.2% for the NSP1, NSP2, NSP3 (ARQ/ARQ), NSP3 (others), NSP4 and 
NSP5, respectively (Table 14). The NSP4 and NSP5 groups in the population of this 
study were more frequent compared to those reported by European Commission (2006). 
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The lower genotype frequency of NSP1 and higher frequency of NSP5 in our sheep 
population as compared to the recently reported average in EU member states is due to 
the requirement of sheep with high susceptibility genotypes of this study. The blood 
samples were collected not randomly, but focused on the breed which is known to carry 
the high risk genotypes. After classification and selection, the sheep used in this 
experiment were Blackhead and Bentheimer breeds. All of the Bentheimer sheep used 
in this study were R5 genotypes, whereas most of the Blackhead sheep carried the R1 
genotype. The European Commission (2004) reported that the ARR allele frequency of 
the Blackhead breed is 70 to 79% and that of the Bentheimer breed is 0 to 9%. 
According to these findings Blackheads are regarded as a scrapie resistant breed and the 
Bentheimer are regarded as a scrapie-susceptible breed. 
 
5.2 PRNP mRNA expression in preimplantation embryos 
 
This study is the first report of PRNP mRNA expression in ovine preimplantation 
embryos. The quantitative gene expression levels in R1 and R5 groups were in the same 
trend showing that relative expression levels were significantly lower at mature oocyte 
and morula stages compared to the levels at immature oocytes and 1-month-old stages. 
However, comparison between R1 and R5 groups demonstrates that PRNP mRNA 
expression levels of R1 immature oocytes and 1-month-old foetuses were more 
abundant than those of R5 group. The present results in ovine embryos showed the same 
trend as the gene levels in bovine embryos; bovine PRNP transcript abundance 
increased at zygote, was decreased along embryonic development and was elevated at 
early foetal stage again (own unpublished data). The increasing of PRNP transcript at 
zygote stage could be due to sperm activity after fertilisation, since PRNP mRNA was 
found in spermatogenic cells of mice (Fujisawa et al. 2004). Moreover, a C-terminally 
truncated isoform of PrPC was shown in bovine (Shaked et al. 1999) and ovine (Ecroyd 
et al. 2004) mature sperm by western immunoblotting. Thus, sperm could be the source 
of PRNP after fertilisation. 
Maternal-zygotic transition (MZT) is a complex phenomenon characterised by the 
initiation of transcription in the embryo and the replacement of maternal mRNA with 
embryonic mRNA (Vigneault et al. 2004). MZT comprises a period of minor gene 
activation in one-cell embryos, followed by a period of major gene activation in two-
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cell embryos in mice (Schultz 1993), occurs at the 4000- to 8000-cell stage in Xenopus 
(Etkin and Balcells 1985) and at the four- to eight-cell stage in humans (reviewed in 
Telford et al. 1990). The bovine MZT occurs at the 8- to 16-cell stage, and is 
characterized by a major onset of transcription, while minor transcription is observed as 
early as the one-cell embryo (Memili and First 1999). A switch from maternal to 
embryonic genome control appears to occur at the 8- to 16-cell stage in sheep embryos. 
As in the cow embryo, a relatively constant pattern of protein synthesis is observed 
during the first three cell cycles (one-, two-, or four-cell embryos), but a distinctly 
different pattern is observed in 16-cell embryos and at later stages (reviewed in Telford 
et al. 1990). Similar to those studies, it seems likely that the minor embryonic 
transcription of the PRNP occurs at zygote stage followed by the major transcription 
after blastocyst stage in cattle and sheep. This implies that PRNP might have role in 
normal embryo development. 
 
5.3 PRNP mRNA and PrPC expression in prenatal foetuses 
 
In order to investigate the expression profile of PRNP transcripts, prenatal stage whole 
foetuses at the 1st month of pregnancy and various tissues of 3- and 5-month-old 
foetuses were used. In addition and for scale up the number of tissues examined, various 
tissues of 2-month-old foetuses (R1 and R5 groups) including brain, cotyledon, heart, 
intestine, kidney, liver, lung and muscle were added into the experiment to identify the 
activation of PRNP mRNA and protein in single organs during this stage. The results 
showed that PRNP mRNA was found in all tissues of 2-month-old foetuses examined. 
At the 3rd and 5th month of pregnancy, the expression patterns of ovine PRNP mRNA 
showed a similar trend in R1 and R5 groups. Comparison of the levels in each tissue 
between the 3rd and 5th month stages shows similar expression in the R5 group. These 
results showed high expression levels of the PRNP mRNA in cerebrum, cerebellum, 
medulla oblongata, cotyledon and spinal cord, while moderate levels were detected in 
lung, heart, intestine and muscle, and low expression levels were detected in liver and 
spleen. This pattern was also similar to the pattern of R1 foetuses at the 5th month of 
pregnancy; nevertheless, it was different from the pattern at the 3rd month which showed 
the same level of the transcript abundance in liver and spleen as in lung, heart, intestine 
and muscle. The higher expression levels in neuron nerval compared to those of the 
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other tissues were in agreement with previous studies (Han et al. 2006, Harris et al. 
1993, Manson et al. 1992, Kubosaki et al. 2000, McLennan et al. 2001, Tichopad et al. 
2003). On the other hand, in non-nerval tissues, the results in this study were not in 
agreement with Han et al. (2006) and Ning et al. (2005) that showed similar expression 
level of the ovine and murine PRNP transcripts in liver as in heart, lung and spleen. 
Moreover, Tichopad et al. (2003) showed a higher abundance of bovine PRNP in liver 
of adult cattle than in lung.  
The ovine PRNP expression levels were stable throughout the prenatal stage in most of 
the foetal tissues investigated. However, the gene abundance levels were decreased in 
cerebrum, and were increased from 3 to 5 months of age in medulla oblongata, heart, 
liver and spleen of both groups. Quantitative real-time PCR was performed to quantify 
the amount of the gene transcripts in these tissues. The results by real time PCR 
supported those results obtained by RT-PCR.  
For the PrPC expression, Amselgruber et al. (2005) presented that PrPC was detected in 
pancreas of bovine prenatal embryos ranging from 7 to 86 cm in crown-rump length. 
The present study demonstrated, for the first time, that the PrPC is expressed in brain, 
cotyledon, heart, intestine, kidney, liver, lung and muscle of ovine prenatal embryos 
since the 2nd month of embryogenesis. Since PrPC expression levels in various tissues of 
R1 and R5 foetuses were in the same trend, and comparison within each tissue shows 
similar level between the two groups, it could be concluded that there is no relationship 
between PRNP genotype and the tissue expression of the PrPC in prenatal foetuses at 
this developing period. 
PrPC is a glycoprotein present at high level in the brain. It is also found in the heart, 
kidney and lung at intermediate levels, but is not detectable in the liver (Bendheim et al. 
1992, Horiuchi et al. 1995). Moudjou et al. (2001) have revealed the presence of PrPC in 
skeletal muscle, uterus, thymus, tongue and liver other than in brain, heart and lung of 
ewes. By a two-size enzyme immunometric assay of that study, the lowest concentration 
of PrPC was shown in the liver. PrPC in brain was found to be between 564-16,000 fold 
more abundant than in liver, and between 20-50 fold more abundant than in the rest of 
tissues mentioned (Moudjou et al. 2001). This present study supports previous studies 
that PrPC was detectable at moderate level in heart, intestine, kidney, lung and muscle; 
however, the level of PrPC detected in liver was as high as in brain in our study. Ikeda et 
al. (1998) demonstrated that PrPC expression was negligible in normal liver tissue, but 
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was found to increase dramatically in diseased livers associated with stellate cell 
activation. It is reported that activated stellate cells undergo metabolic alterations which 
influence the production of nerve-related proteins such as N-CAM (Knittel et al. 1996) 
or GFAP (Niki et al. 1996), respectively, in rats. Moreover, Manson et al. (1992) have 
suggested that PrPC may function as a neural cell receptor and directing and/or 
maintaining the architecture of the nervous system. Therefore, the demonstration of 
high PrPC levels in brain and liver by western blot is consistent with these views. 
Prion protein is a cell surface glycosylated protein with two N-glycosylation sites; 
therefore, forms of mature PrPC or glycoforms are found with different degrees of 
glycosylation. The glycoform signature of PrPC in the brain, as obtained with most anti-
PrP antibodies described in the literature, is in general characterised by the presence of 
three bands with decreasing intensity, representing the bi-, mono- and unglycosylated 
isoform of PrP of ~33, 30 and 28 kDa, respectively (Moudjou et al. 2001). In this study, 
PrPC could be detected by loading protein extracts from only 1 mg of tissue per lane of 
almost all tissues except cotyledon. The PrPC reactive bands detected in cotyledon tissue 
of both groups were very weak and unclear. Due to these results, western blot analysis 
was done in addition in double concentration of protein extracted from cotyledon of 2-, 
3- and 5-month-old foetuses (R1 and R5 groups). The results clearly revealed the 
existence of PrPC with the molecular weight of ~ 30 kDa in cotyledon of 3- and 5-
month-old R1 and R5 foetuses, and assured the presence of PrPC in the 2-month-old 
foetuses (Figure 23). Interestingly, most of foetal tissues examined produced mainly the 
biglycosylated isoform, and minimally the monoglycosylated isoform of PrPC. 
Nevertheless, the cotyledon of both R1 and R5 foetuses produced only the 
monoglycosylated isoform. These suggest that the PrPC in foetal cotyledon is 
differentially glycosylated from other foetal tissues, and could be involved in different 
physiological functions of the protein. 
The study of PrPC expression in prenatal foetuses established that the levels of PrPC in 
some tissues were not related to the levels of the gene transcript. At 2 months of age, 
PRNP mRNA level(s) were high in brain and cotyledon, and low in liver. On the other 
hand, the PrPC was highly expressed in brain and liver, and was very low in cotyledon. 
Liver is an organ which plays a major role in detoxification, blood protein formation 
and several metabolism functions. In the foetus, blood leaving the placenta via the 
umbilical vein passes through the ductus venosus and other veins of the foetal liver 
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(Valadian and Porter 1977). Since PrPC was found on peripheral blood mononuclear 
cells (Halliday et al. 2005), the accumulation of PrPC in foetal liver might have resulted 
from the circulation of PrPC from its maternal placenta. Our finding suggested more that 
organs, for which infectivity has been demonstrated (brain and intestine), contain more 
PrPC than tissues shown not to support infection (cotyledon, heart, lung and muscle) 
(Hadlow et al. 1982). 
 
Figure 23: Western blot analysis, revealing the immuno reactive bands of PrPC in 
foetal cotyledon of scrapie-resistant (R1) and high susceptibility (R5) groups at 2, 3 and 
5 months of pregnancy. Protein extracts from 2 mg of each sample were loaded per 
lane. The foetal brains were used as positive control  
 
5.4 In situ analysis of PRNP mRNA and PrPC expression in 1-month-old foetuses 
 
Localisation of the mRNA and protein in tissues is an important tool to understand the 
function of target genes at the cellular level. In the present study, fluorescent in situ 
hybridisation and immunohistochemistry were used as a tool for localisation of the 
PRNP transcript and the PrPC, respectively, in 1-month-old foetuses and ovaries.  
The results presented here demonstrate for the first time that the ovine PRNP mRNA is 
distributed not only in neural cells, but was also detected in many non-neural organs 
such as dermatome, vertebral column, heart, liver and kidney of sheep foetuses since the 
1 month of age. The in situ hybridisation signals were detected in the brain and liver of 
control sections which were hybridised with sense RNA probe as well; however, the 
signals in the sections with antisense probe were intensely labelled above the control 
one. At this time of age, PrPC was localised in developing brain, heart and kidney. 
These results correlate well with several studies demonstrating a distribution of PRNP 
mRNA in mouse and chicken foetuses during embryonic development. PRNP 
transcripts were found in developing brain and spinal cord of embryonic day 13.5 as 
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well as in ganglia and nerves of the central and peripheral nervous system of embryonic 
day 16.5 in mice. The gene transcripts were also detected in specific non-neuronal cell 
populations such as intestine, dental lamina, tooth bud and kidney of the 13.5 and 16.5 
day embryos, and in extra-embryonic tissues from day 6.5. No PRNP transcript could be 
detected in 6.5- or 9.5-day-old mouse embryos (Manson et al. 1992). In contrast to the 
study of Manson and co-workers, Miele et al. (2003) presented the activation of PRNP 
transcription since the day 8.5 and 9.5 of mouse embryogenesis. Eventhough the gene 
transcript was not found at day 8.5, it was widespread throughout all regions of the 
developing brain such as telencephalic, mesencephalic and metencephalic vesicles, and 
the developing neural tube at day 9.5. During chicken embryogenesis, the mRNA for  
a chicken PRNP was found in the brain and spinal cord as early as embryonic day 6 (the 
earliest stage examined). This transcript was also detectable in dorsal root ganglia, 
retina, aorta, gizzard, intestine and heart of embryonic day 11 (Harris et al. 1993). The 
expression levels of PRNP mRNA increased 8-fold between days 1 to 42 of postnatal 
development in mouse brains. The PrPC level has also increased over this period, most 
significant from days 1 to 10 (Miele et al. 2003). PRNP mRNA and protein continue to 
be expressed at high level in the central nervous system of adult animal (Bendheim et al. 
1992, Han et al. 2006, Harris et al. 1993, Kubosaki et al. 2000, Manson et al. 1992, 
McBride et al. 1992, McLennan et al. 2001, Tichopad et al. 2003). The mRNA was 
predominantly localised in the brain within pyramidal cells of the hippocampus, large 
neurons of the thalamus and neocortex and Purkinje cells of the cerebellum (Tanji et al. 
1995). Furthermore, the regulation of PRNP mRNA expression by nerve growth factor 
(NGF) has been shown in a clonal cell line, PC12 cells, (Wion et al. 1988) and many 
regions of postnatal mouse brain (Mobley et al. 1988). The expression of PRNP mRNA 
and PrPC in developing brain and neural tube started at the early stage of foetal 
development and its continued expression in adult brain demonstrate that PRNP might 
be critical to neuronal differentiation or survival during the development of the central 
and peripheral nervous system.  
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5.5 PRNP mRNA and PrPC expression in reproductive tissues of ewes 
 
The expression patterns of PRNP transcript in reproductive organs of R1 and R5 ewes 
were not different at all stages studied. Comparison among tissues within each group 
displays the similar expression level of PRNP transcript in ovary, oviduct, endometrium 
and myometrium, whereas the highest level, as high as in brain (data not shown), was 
found in caruncle of both groups. Between R1 and R5 ewes within each stage, the 
expression level of PRNP mRNA in ovary, oviduct, endometrium and myometrium 
were not different, while the levels in R1 caruncle were higher than that in R5 caruncle 
at the 1st month of pregnancy. However, western blot analysis revealed a similar 
abundance of PrPC in R1 and R5 caruncle, but higher abundant when compared to the 
level in other tissues. Moreover, lower expression levels of PrPC were detected in 
oviduct as compared to ovary, endometrium and myometrium of both groups. The 
ruminant placenta is classified as synepitheliochorial (Wooding and Flint 1994) and has 
a cotyledonary organization in which both foetal and maternal villi are discernible as 
discrete structures (placentome) on the uterine epithelium. Intimate contact between 
maternal and foetal tissue occurs only in the placentome (comprising the foetal 
cotyledon and maternal caruncle), which is the most highly vascularized portion of the 
placenta. This study also found that the ovine PRNP mRNA and PrPC levels were 
highest in caruncle compared to other tissues investigated. Moreover, the PrPC was 
abundant at low level in the cotyledon of 2-month-old foetuses, while the levels were 
high at the 3rd and 5th month of pregnancy. These results were in agreement with 
Kubosaki et al. (2000) who showed the stronger signals of PRNP mRNA in sheep 
caruncle than the signals in myometrium by in situ hybridisation. Similarly, Tuo et al. 
(2001) showed higher expression level of PrPC in caruncular endometrium than in 
intercaruncular endometrium, myometrium, oviduct and ovary by western blot analysis. 
The results from this study suggest that the sheep placenta, caruncle especially, may be 
an important organ for the conversion of PrPC to PrPSc, and also substantiate the 
probability that placenta plays an important role in natural transmission of scrapie. Even 
Onodera et al. (1993) displayed the undetectable level of PrPSc in the placenta of 
Corriedale and Suffolk sheep at the 3rd and 5th month of pregnancy, respectively,  
a significant amount of scrapie agent has been isolated from the placenta of pregnant 
ewes by Race et al. (1998). 
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The present study has demonstrated for the first time that the PRNP transcript was 
localised in oocytes, granulosa cells, theca cells, ovarian cortex, ovarian medulla and 
corpus luteum. Interestingly, the PrPC was detectable only in ovarian cortex and ovarian 
medulla, but not in the oocyte, granulosa and theca cells. In sheep, the ovum is released 
from the ovary at estrus and reaches the uterus through the oviduct within 3 to 4 days. 
The embryo will not hatch from the zona pellucida until it is in the uterus. Tuo et al. 
(2001) and Hadlow et al. (1979) demonstrated that PrPC, but not the PrPSc, was present 
in the ovary and oviduct. These findings prove the recent observations on the prevention 
of TSE transmission (maternal-vertical) in bovine and ovine preimplantation embryos 
and foetuses using embryo transfer (Foote et al. 1993, Foster et al. 2004, Wang et al. 
2002, 2001, Wrathall et al. 2002). The prevention of the TSE transmission by embryo 
transfer procedures, which are neither transmitted to offspring via the embryo nor to 
recipient animals, even when the embryos are collected from the TSE-infected donors, 
might have resulted from the lack of PrPC in oocytes, the protection of zona pellucida 
and the lack of PrPSc in ovary and oviduct. In addition, the fact that PrPC was not 
expressed in oocyte, granulosa and theca cells is meaningful for the use of reproduction 
biotechnologies, which aim at the application of these cells (embryo transfer, in-vitro-
fertilisation/production). In the uterus of non-pregnant ewes, PrPC was shown in 
caruncular endometrium and myometrium. The level of this protein was increased in the 
pregnant caruncular endometrium as compared to non-pregnant one (Tuo et al. 2001). 
Throughout the pregnancy period, PRNP mRNA expression level was increased in the 
caruncle. Moreover, both RT-PCR and western blot analysis revealed the higher 
expression levels of the mRNA and protein in the caruncle than those of other tissues 
studied. Since PrPSc was detected only in caruncular endometrium and cotyledonary 
chorioallantoic of the placentome from pregnant infected ewes (Tuo et al. 2001), it 
appears that PrPSc is present in tissue known to express high level of PrPC. In addition, 
PrPC was not detectable in the amnion during pregnancy period (Tuo et al. 2001); 
therefore, the foetus might be separated from the PrPSc-rich placental tissues by the 
PrPC-free amnion.  
The tissue distribution of PrPC in sheep was first studied by Horiushi et al. (1995). In 
2001, Mohammed et al. displayed the presence of PrPC in some additional tissues from 
sheep with each ARR/ARQ, ARR/AHQ or ARQ/VRQ genotypes. Unfortunately, due to 
the low number of sheep tested, the relationship between animal genotype for the PRNP 
Discussion                                                                                                                                                    94 
locus and tissue expression of PrPC could not be determined. However, studies with 
permissive cells expressing two different PRNP variants (ARR and VRQ) indicated that 
cell biological properties of ovine PRNP can vary with natural polymorphisms and raise 
the possibility that differential interactions of PRNP variants with the cellular 
machinery may contribute to permissiveness or resistance to prion multiplication 
(Sabuncu et al. 2005). Moreover, several studies demonstrated that the accumulation of 
PrPSc in placenta of ewes is determined by the foetal PRNP genotype and the pregnancy 
status of scrapie-infected ewes. The PrPSc was detected in placentomes of ewes with 
171QQ conceptuses, but not in those with 171QR conceptuses or in non-pregnant uterus 
of infected ewes (Andreoletti et al. 2002, Tuo et al. 2002). While the accumulation level 
of PrPSc in the uterus was decreased throughout the pregnancy period, it was increased 
in the caruncle (Tuo et al. 2002). PrPC is a primary substrate for the conformation 
change of the PrPC into PrPSc. The amount of PrPC is a rate-limiting step in the 
development of the prion disease. This present study showed an effect the PRNP 
variants on the gene expression level in caruncle during the gestation period; PRNP 
mRNA levels were increased in R5 caruncle, while it seems to be stable in R1 caruncle. 
Nevertheless, no relationship between the gene variants, and the normal protein 
distribution was observed in the present study. Interestingly, all female reproductive 
organs examined in this study showed only bands of the biglycosylated isoform. This 
contrasts to previous studies that PrPC reactive bands of either bi- or hyperglycosylated 
isoformes were mostly found (Ikada et al. 1998, Mohammed et al. 2001, Pammer et al. 
1998, Tuo et al. 2001). 
In conclusion, knowledge about the switch-on period of the prion protein gene both on 
mRNA and protein levels during prenatal stage of mammalian embryos was not 
available so far. In order to understand the mechanism and function of PrPC in 
embryogenesis, this information is of a great importance. This study is the first to report 
the expression of PRNP mRNA and PrPC during prenatal stages of sheep. The relative 
abundances of PRNP mRNA and protein have been documented in various tissues of 
prenatal embryos as well as reproductive tissues of ewes. The mRNA and protein were 
found in many tissues of preimplantation stages foetuses as early as 1 month of age, and 
was detected in all tissues studied at the 2nd month; however, the levels of those 
activities were different between tissues. In 1-month-old foetuses, PRNP mRNA was 
expressed in developing brain, heart, kidney, liver, vertebral column and dermatome, 
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while the PrPC was detectable only in the brain, heart and kidney. Both mRNA and 
protein were detected in all foetal tissues examined including brain, cotyledon, heart, 
intestine, kidney, liver, lung, muscle and spleen since at the 2nd month (Table  15). With 
the exception of the foetal cotyledon and liver, the levels of PrPC correlate well with the 
relative mRNA expression levels in sheep tissues. This study displayed that the mRNA 
was high in cotyledon, but was low in liver of the foetuses. In contrast, PrPC were found 
at high level in liver but low level in cotyledon. These might be involved in the function 
of PRNP gene. In female reproductive organs of pregnant ewes, both PRNP mRNA and 
PrPC were found at similar level when compared between ovary, oviduct, endometrium 
and myometrium. The mRNA and the protein were highest and increased throughout 
the gestation period in R5 caruncle. In addtion, the studies in R1 and R5 genotypes 
sheep showed no relationship between PRNP genotypes and the mRNA and protein 
expression levels in the prenatal foetuses. Since the levels of PRNP mRNA in R5 
caruncle were higher than that of R1 caruncle, the PRNP genotype (according to the 
polymorphisms at codons 136, 154 and 171) may have an effect on the gene expression 
level in caruncle tissue of ewes.  
In the present study, the expressions of PRNP transcripts were observed as early as at 
the preimplantation developmental stage. The level was increased immediately after 
fertilisation compared to the oocyte stage in cattle (own unpublished data). These 
suggest that the minor transcription activity of prion protein occur at zygote stage, and 
the PrPC might have role in normal embryo development. The increase of the gene 
transcript at zygote stage might have resulted from sperm activity, since a C-terminally 
truncated PrPC isoform was found in bovine (Shaked et al. 1999) and ovine (Ecroyd et 
al. 2004) mature sperm by the western immunoblotting; thus, sperm could be one source 
of PRNP in the zygote. The PRNP mRNA expression profiling should be performed in 
some additional stages of ovine preimplantation embryos to clarify the minor and major 
embryonic activation of this gene. The protein expression profiling in those 
preimplantation embryos, and, moreover, silencing the gene at zygote stage might give 
us the clues to its physiological role. In addition, PRNP expression both at mRNA and 
protein levels could be investigated in the earlier stages of before 1 month of age in 
vitro in order to define the exact timing and localisation of PRNP transcriptional and 
translational activations during the prenatal stage. 
Table 15: PRNP mRNA and PrPC expression in 1- 2- and 3-month-old foetuses 
 
Month of age Brain Cotyledon 
Spinal 
cord 
Heart Intestine Kidney Liver Lung Muscle Spleen 
Vertebral 
column 
Eyes 
Ovine PRNP 
  -1 month  
  -2 months 
  -3 months 
 
+ 
+ 
+ 
 
nd 
+ 
+ 
 
nd 
nd 
+ 
 
+ 
+ 
+ 
 
nd 
+ 
+ 
 
+ 
+ 
nd 
 
+ 
+ 
+ 
 
nd 
+ 
+ 
 
nd 
+ 
+ 
 
nd 
nd 
+ 
 
+ 
nd 
nd 
 
+ 
nd 
nd 
Ovine PrPC 
  -1 month 
  -2 months 
 
+ 
+ 
 
nd 
+ 
 
nd 
nd 
 
+ 
+ 
 
nd 
+ 
 
+ 
+ 
 
- 
+ 
 
nd 
+ 
 
nd 
+ 
 
nd 
nd 
 
- 
nd 
 
- 
nd 
+ present 
- absent 
ns = not done 
 
 
 
 
 
 
D
iscu
ssio
n
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 96
 
Summary                                                                                                                                                    97   
6 Summary 
 
This study was carried out with the main objectives (i) to determine whether the 
polymorphisms at codons 136, 154 and 171 of PRNP locus affect the gene expression, 
(ii) to observe the exact timing of PRNP transcript and protein activation, and (iii) to 
investigate the expression profile of the PRNP in preimplantation embryos, reproductive 
organs of ewes and various tissues of their foetuses during prenatal stage. To full fill 
these objectives, sheep with scrapie resistance genotype (R1 group; ARR/ARR) and 
high susceptible to scrapie genotypes (R5 group; VRQ/ARQ, VRQ/ARH, VRQ/VRQ) 
were used as an animal model. The samples were immature and mature oocytes, morula 
stage embryos, 1-month-old foetuses, various tissues such as brain, cotyledon, spinal 
cord, heart, intestine, liver, lung, muscle and spleen from 3- and 5-month-old foetuses 
as well as ovary, oviduct, endometrium, myometrium and caruncle from 1, 3 and 5 
months pregnant ewes. 
For experiments using real time PCR, mRNA has been isolated using oligo (dT)25 
attached magnetic beads from three independent pools containing 15 to 20 immature 
oocytes, or three members of each mature oocytes or embryos. mRNA was reverse 
transcribed to cDNA with oligo dT(12)N primer. Real time RT-PCR was done using 
those samples and 1-month-old foetuses (n=2). The results displayed expression of the 
gene in all samples examined. The relative abundance of the gene transcript as 
compared to the level of the ovine Histone H2a was higher in immature oocytes and  
1-month-old foetuses and lower in mature oocytes and morula stage embryos of both 
groups (p≤0.05). Significant effects of the PRNP genotype on the mRNA level were 
shown in immature oocytes and 1-month-old stages as indicated by the higher levels in 
R1 samples than those of R5 samples. 
To identify the gene transcript and to compare the expression level among tissues, 
stages and risk groups (n=2 for each), semi-quantitative RT-PCR was performed by 
using 18S-rRNA as an internal standard. Total RNA was isolated from samples using 
TRIZOLE reagent and then subjected to DNase digestion. Finally, 1 µg of total RNA 
was reverse transcribed to cDNA with oligo dT(12)N and random primers. The results 
revealed that PRNP mRNA was detectable in all maternal and foetal tissues throughout 
the gestation. The gene mRNA level was highest in caruncle, whereas the levels, which 
seem to be equal and stable during the gestation, were low in ovary, oviduct, 
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endometrium and myometrium. Interestingly, while the mRNA level in R1 caruncle was 
stable through the pregnancy period, the level increased from the 1st to 3rd months, and 
decreased at the 5th month in R5 caruncle. To confirm these changes, real time PCR was 
performed. The quantitative expression levels in R1 and R5 caruncle support the results 
by RT-PCR. Mean and standard error in R1 caruncle at the 1st, 3rd and 5th months of 
pregnancy were 48.1 ± 19.6, 42.0 ± 6.1 and 26.3 ± 2.3, respectively, and that of R5 
caruncle were 17.2 ± 0.6, 44.9 ± 2.6 and 28.7 ± 12.4, respectively.  
In both R1 and R5 prenatal foetuses, PRNP transcript levels were high in spinal cord, 
cotyledon and all regions of the brain such as cerebrum, cerebellum and medulla 
oblongata. Moderate levels were found in heart, intestine, lung and muscle, and low 
levels were observed in liver and spleen. The level of the gene transcript from 3 to 5 
months of age was increased in spinal cord, but stable in cerebellum, intestine, lung and 
muscle of both groups. Interestingly, while the level was stable in R1 cerebrum and R1 
medulla oblongata, it was changed through the gestation in those of R5 foetuses. 
Moreover, a differentiation in the gene expression pattern between R1 and R5 foetuses 
was observed in the heart, liver and spleen. Therefore, real time PCR was used to 
quantify these differences. The results showed that PRNP levels relative to the levels of 
18S-rRNA in R1 cerebrum, medulla oblongata, heart, liver and spleen were 47.9, 41.4, 
4.3, 2.2 and 5.5, respectively, at the 3rd month of pregnancy, while 35.1, 50.1, 7.0, 8.0 
and 9.4, respectively, at the 5th month. From real time PCR analysis results, it seems 
likely that PRNP expression level was decreased through the pregnancy period in R1 
foetal cerebrum, while it was increased in the rest of tissues. Similar to R5 foetuses, at 
the 3rd month of pregnancy, PRNP mRNA relative abundance levels in cerebrum and 
medulla oblongata were higher than those in heart, liver and spleen. The levels at this 
stage were 32.1, 33.6, 7.3, 2.4 and 4.3, respectively. At the 5th month, the level in R5 
medulla oblongata (67.3) was also higher than those of cerebrum (24.6), heart (7.5), 
liver (2.5) and spleen (7.7).    
Since the gene transcript was detected in all tissues of 3-month-old foetuses, RT-PCR 
was carried out in brain, cotyledon, heart, intestine, kidney, liver, lung and muscle of 2-
month-old foetuses of both groups. Results revealed the presence of the gene transcripts 
in all tissues investigated. The gene expression patterns were in the same trend as that of 
3- and 5-month-old foetuses as indicated by the high expression level in brain and 
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cotyledon, moderate level in heart, intestine, kidney, lung and muscle, and low level in 
liver. 
Western blot was performed in reproductive tissues of 1-month pregnant ewes and those 
tissues from 2-month-old foetuses to define whether the prion protein (PrPC) is activated 
at this stage. The results displayed the immuno reactive bands corresponding to the PrPC 
in all tissues investigated of both groups. Interestingly, while the PrPC level in most 
tissues correlated well with the level of PRNP transcript, the level of PrPC in foetal 
cotyledon was very low and the level in foetal liver was as high as that in brain.  
As PRNP transcript and protein were detected in 1-month-old foetuses and ovaries, 
fluorescent in situ hybridisation (FISH) and immunohistochemistry (IHC) were 
performed to localise the gene mRNA and protein, respectively, on these samples.  
FISH was carried out on 7 to 10 µm cryostat sections of snap frozen tissues. A non-
radioactive probe with a reporter molecule digoxigenin (DIG) detected by indirect 
method with the help of tyramide signal amplification (TSA, fluorophore system) was 
applied in this experiment. The control sections hybridised with sense RNA probe were 
done in parallel. On the other hand, IHC was performed on 5 to 7 µm cryostat sections 
with the help of avidin-biotin complex (ABC). The immuno-complexes were visualised 
using 3-amino-9-ethylcarbazole (AEC) substrate. Sections devoid of specific staining 
with the PrP antibody were used as control for the IHC. Staining intensity is a function 
of the enzyme activity and improved sensitivity can be achieved by increasing the 
number of enzyme molecules bound to the tissue. The precipitation of the tyramide  
(a phenolic compound) after oxidation and the multiple binding sites between the 
tetravalent avidin and biotinylated antibodies (bound to the antigen) are ideal for 
achieving this amplification. Both of FISH and IHC were pre-optimised in adult brains 
which were done in parallel as positive control through out the experiment. The results 
showed that both of PRNP mRNA and PrPC were localised in developing brain, heart 
and kidney of 1-month-old foetuses of both groups, whereas only the mRNA, but not 
the PrPC, was found in liver, vertebral column and dermatome. The gene transcript was 
also localised in oocytes, granulosa and theca cells, and dispersed in ovarian cortex, 
medulla and corpus luteum. However, the PrPC was detected only in the ovarian cortex 
and medulla of 1-month pregnant ovaries of both groups. 
In conclusion, this study is the first report of PRNP mRNA and PrPC expression in 
ovine preimplantation embryos and prenatal foetuses. The levels of PRNP transcript in 
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immature oocytes and 1-month-old foetuses were significantly higher (p≤0.05) than 
those in mature oocytes and morula stage embryos. The PRNP mRNA is activated in 
brain, vertebral column, dermatome, heart, liver and kidney as early as the 1st month of 
embryogenesis. At this time, PrPC is produced in the brain, heart and kidney. 
Furthermore, the protein activation in cotyledon, intestine, liver, lung and muscle occur 
in between the 1st and 2nd months of foetal development. Throughout the prenatal 
stages, the mRNA levels were high in spinal cord, cotyledon and all regions of brain of 
the foetuses. Moderate levels were shown in intestine, lung and muscle, and low levels 
were detected in liver and spleen. In reproductive organs of ewes, high expression level 
of the gene transcript was found in caruncle of ewes, while the level in ovary, oviduct, 
endometrium and myometrium were moderate. With the exception in foetal cotyledon 
and liver, the level of PrPC correlates well with the relative mRNA expression level in 
sheep tissues. The results of this study revealed a correlation between the reported 
PRNP polymorphisms and the gene mRNA level in immature oocytes and 1-month-old 
stages. Moreover, it seems likely that these polymorphisms have an effect on the gene 
expression level in caruncle of ewes. 
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7 Zusammenfassung 
 
Diese Untersuchung wurde mit den folgenden Hauptgesichtspunkten durchgeführt (i) 
zur Feststellung der Beeinflussung der Genexpression der Polymorphismen an Codon 
136, 154 und 171 des PRNP Genortes, (ii) zur Untersuchung der zeitlichen Regulierung 
der PRNP Transkripte und der Proteinaktivierung und (iii) zur Untersuchung des 
Expressionsprofils des PRNP in präimplantativen Embryos, reproduktiven Geweben 
von Mutterschafen und verschiedenen Geweben ihrer Föten während der pränatalen 
Stadien. Zur Untersuchung wurden Schafe mit Scrapie resistenten Genotypen (R1 
Gruppe; ARR/ARR) und für Scrapie hoch anfällige Genotypen (R5 Gruppe; 
VRQ/ARQ, VRQ/ARH, VRQ/VRQ) als Tiermodell verwendet. Als Proben wurden 
unreife und reife Oozyten, Embryonen im Morulastadium, einmonatige Föten, 
verschiedene Gewebe wie Gehirn, Kotyledonen, Rückenmark, Herz, Darm, Leber, 
Lunge, Muskel und Milz von drei- und fünfmonatigen Föten ebenso wie Ovar, Eileiter, 
Endometrium, Myometrium und Karunkel von Mutterschaften im ersten, dritten und 
fünften Trächtigkeitsmonat verwendet. 
Für die Experimente unter Verwendung der Real Time PCR wurde mRNA mit Oligo 
(dT)25 angehefteten magnetischen Beads aus drei unabhängigen Pools mit 15 bis 20 
unreifen Oozyten, oder aus drei Teilen von jeder reifen Oozyte oder jedem Embryo, 
isoliert. Die mRNA wurde entgegengesetzt mit Oligo dT(12)N Primern zu cDNA 
transkribiert. Die Real-Time RT-PCR wurde mit diesen Proben und den einmonatigen 
Föten (n=2) durchgeführt. Die Ergebnisse zeigten eine Expression der Gene in allen 
untersuchten Proben. Die relative Anwesenheit der Gentranskripte war verglichen zum 
Level des ovinen Histone H2a in unreifen Oozyten und einmonatigen Föten höher und 
in reifen Oozyten und Embryonen im Morulastadium beider Gruppen niedriger 
(p≤0,05). Signifikante Effekte des PRNP Genotyps auf dem mRNA Level konnten, wie 
durch das höhere Level in R1 Proben verglichen mit den R5 Proben bereits angedeutet, 
in den unreifen Oozyten und im Ein-Monats-Stadium gezeigt werden. Zur Identifikation 
der Gentranskripte und zum Vergleich der Expressionslevel zwischen Geweben, Stadien 
und Risikogruppen (jeweils n=2), wurde eine semi-quantitative RT-PCR, unter 
Verwendung von 18S-rRNA als internem Standard, durchgeführt. Die gesamt-RNA 
wurde mit TRIZOL Reagenz aus den Proben isoliert und ein DNase Verdau 
durchgeführt. Schließlich wurde 1 µg der gesamten RNA entgegengesetzt mit Oligo 
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dT(12)N und Random-Primern zu cDNA transkribiert. Das Ergebnis zeigte, dass die 
PRNP mRNA in allen maternalen und fötalen Geweben während der Trächtigkeit 
detektierbar ist. Das mRNA Level des Gens war am höchsten im Karunkel, während das 
Level, welches scheinbar gleichbleibend und stabil während der Trächtigkeit war, im 
Eierstock, Eileiter, Endometrium und Myometrium niedrig war. Während das mRNA 
Level im R1 Karunkel während der Trächtigkeit stabil war, erhöhte sich das Level 
interessanterweise vom ersten bis zum dritten Monat und verringerte sich im fünften 
Monat im R5 Karunkel. Zur Bestätigung dieser Veränderungen wurde eine Real-Time 
PCR durchgeführt. Die quantitativen Expressionslevel in R1 und R5 Karunkeln 
sicherten die Ergebnisse der RT-PCR ab. Die Durchschnitte und Standardfehler in R1 
Karunkeln im ersten, dritten und fünften Trächtigkeitsmonat waren jeweils 48,1 ± 19,6; 
42,0 ± 6,1 und 26,3 ± 2,3 und in R5 Karunkeln jeweils 17,2 ± 0,6; 44,9 ± 2,6 und 28,7 ± 
12,4.  
In den beiden R1 und R5 pränatalen Föten waren die PRNP Transkript-Level höher im 
Rückenmark, Kotyledonen und allen Regionen des Gehirns wie Cerebrum, Cerebellum 
und Medulla oblongata. Mittlere Level wurden im Herz, Darm, Lunge und Muskel 
gefunden, niedrige Level wurden in Leber und Milz festgestellt. Die Levels der 
Gentranskripte im Rückenmark stiegen während des Alters von drei zu fünf Monaten, 
blieben jedoch in Cerebellum, Darm, Lunge und Muskel beider Gruppen stabil. 
Während das Level im R1 Cerebrum und R1 Medulla oblongata stabil war, veränderte 
es sich während der Gestation der R5 Föten. Weiterhin wurde eine Differenzierung der 
Muster der Genexpression zwischen den R1 und R5 Föten in Herz, Leber und Milz 
gefunden. Daher wurde eine Real-Time PCR zur Quantifizierung dieser Unterschiede 
durchgeführt. Die Ergebnisse zeigten, dass die PRNP Level relativ zu den Leveln der 
18S-rRNA im R1 Cerebrum, Medulla oblongata, Herz, Leber und Milz im dritten 
Monat der Trächtigkeit jeweils 47,9; 41,4; 4,3; 2,2 und 5,5 waren, während sie während 
dem fünften Monat der Trächtigkeit jeweils 35,1; 50,1; 7,0; 8,0 und 9,4 waren. Aus den 
Ergebnissen der Real-Time PCR Analyse schien es, dass das PRNP Expressionslevel 
während der Trächtigkeitsperiode im R1 fötalen Cerebrum verringert war, während es 
im restlichen Gewebe erhöht war. Ähnlich der R5 Föten während des dritten Monats der 
Trächtigkeit waren die Level der relativen Mengen der PRNP mRNA in Cerebrum und 
Medulla oblongata höher als die in Herz, Leber und Milz. Die Level dieser Stadien 
waren jeweils 32,1; 33,6; 7,3; 2,4 und 4,3. Im fünften Monat war das Level in R5 
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Medulla oblongata (67,3) ebenfalls höher als das von Cerebrum (24,6), Herz (7,5), 
Leber (2,5) und Milz (7,7).  
Da das Gentranskript in allen Geweben des dreimonatigen Fötus detektiert wurde, 
wurde eine RT-PCR im Gehirn, Kotyledonen, Herz, Darm, Niere, Leber, Lunge und 
Muskel von zweimonatigen Föten beider Gruppen durchgeführt. Die Ergebnisse zeigten 
die Präsenz der Gentranskripte in allen untersuchten Geweben. Die Muster der 
Genexpression waren im gleichen Trend wie die der drei- und fünfmonatigen Föten, wie 
gezeigt durch höhere Expressionslevel in Gehirn und Kotyledonen, mittlere Level in 
Herz, Darm, Niere, Lunge und Muskel sowie niedrige Level in der Leber.  
Ein Westernblot wurde in den reproduktiven Geweben der im ersten Monat trächtigen 
Mutterschafe und der Gewebe der zweimonatigen Föten zur Feststellung, ob das Prion-
Protein (PrPC) in diesen Stadien aktiviert ist, durchgeführt. Die Ergebnisse stellten die 
zu dem PrPC korrespondierenden immunoreaktiven Banden in allen untersuchten 
Stadien in beiden Gruppen dar. Während das PrPC Level in den meisten Geweben gut 
mit dem Level der PRNP Transkripte korrelierte, war das Level des PrPC im fötalen 
Kotyledon sehr niedrig und das Level in der fötalen Leber war ebenso hoch wie das im 
Gehirn.  
Aufgrund der Detektion von PRNP Transkript und Protein in einmonatigen Föten und 
in Ovarien, wurden fluoreszenz in situ Hybridisierung (FISH) und Immunohistochemie 
(ICH) zur Lokalisation der mRNA und des Proteins des Gens in diesen Proben 
durchgeführt. FISH wurde in 7 bis 10 µm Cryostat Schnitten von gefrorenem Gewebe 
durchgeführt. Eine nicht-radioaktive Probe mit dem Reportermolekül Digoxigenin 
(DIG), detektiert durch eine indirekte Methode mit Hilfe von Tyramide-Signal 
Amplifikation (TSA), wurde in diesem Experiment angewandt. Die Kontrollschnitte 
wurden mit sense RNA Proben parallel hybridisiert. Auf der anderen Seite wurde eine 
ICH auf 5 bis 7 µm Cryostat-Schnitten mit Hilfe von Avidin-Biotin Komplexen (ABC) 
durchgeführt. Die Immuno-Komplexe wurden mit 3-Amino-9-Ethylcarbazole (AEC) 
Substraten visualisiert. Die Schnitte ohne spezifische Färbung mit PrP Antikörpern 
wurden als Kontrolle für die ICH verwendet. Die Intensität der Färbung ist eine 
Funktion der Enzymaktivität und eine verbesserte Sensibilität kann durch eine 
Erhöhung der Anzahl von Enzymmolekülen, welche an das Gewebe binden, erreicht 
werden. Die Ausfällung der Tyramide (phenolische Komponenten) nach der Oxidation 
und die multiplen Bindestellen zwischen den tetravalenten Avidin und biotinylierten 
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Antikörpern (binden zu dem Antigen) sind ideal für das Erreichen dieser Amplifikation. 
Beide, FISH und ICH, wurden in adulten Gehirnen parallel prä-optimiert und als 
positive Kontrolle während des Experiments verwendet. Die Ergebnisse zeigten, dass 
beide PRNP mRNA und PrPC im sich entwickelnden Gehirn, Herz und Niere der 
einmonatigen Föten beider Gruppen lokalisiert sind, während nur die mRNA jedoch 
nicht das PrPC in Leber, Wirbelsäule und Dermatom gefunden wurde. Das 
Gentranskript war ebenfalls in Oozyten, Granulosa und Thekazellen lokalisiert sowie in 
der Ovarrinde, im Ovarmark und im Gelbkörper zu finden. Das PrPC wurde jedoch nur 
der Ovarrinde und Mark in den Ovarien der Tiere im ersten Trächtigkeitsmonat in 
beiden Gruppen festgestellt.  
Zusammenfassend kann man sagen, dass diese Untersuchung zum ersten Mal die PRNP 
mRNA und PrPC Expression in ovinen Präimplantations-Embryonen und pränatalen 
Föten zeigt. Die Level der PRNP Transkripte in unreifen Oozyten und einmonatigen 
Föten waren signifikant höher (p≤0,05) als die in reifen Oozyten und Embryonen im 
Morulastadium. Die PRNP mRNA ist im Gehirn, Wirbelsäule, Dermatom, Herz, Leber, 
Lunge und Niere bereits während des ersten Monats der Embryogenese aktiv. Zu dieser 
Zeit wird PrPC im Gehirn, Herz und Niere produziert. Darüberhinaus erfolgt die 
Proteinaktivierung in Kotyledonen, Darm, Leber, Lunge und Muskel während dem 
ersten und zweiten Monats der fötalen Entwicklung. Während der pränatalen Stadien 
sind die mRNA Level im Rückenmark, Kotyledonen und allen Regionen des Gehirns 
der Föten hoch. Mittlere Level wurden im Darm, Lunge und Muskel nachgewiesen und 
niedrige Level wurden in Leber und Milz detektiert. In den Reproduktionsorganen der 
Mutterschafe wurden hohe Expressionslevel im Karunkel der Mutterschafe gefunden, 
während die Level in Eierstock, Eileiter, Endometrium und Myometrium mittel waren. 
Mit Ausnahme des fötalen Kotyledon und der Leber korrelierten die Level des PrPC gut 
mit dem relativen mRNA Expressionslevel im Gewebe des Schafs. Die Ergebnisse 
dieser Untersuchung ergaben eine Korrelation zwischen den gezeigten PRNP 
Polymorphismen und dem mRNA Level des Gens in unreifen Oozyten und 
einmonatigen Stadien. Darüberhinaus, scheint es gut möglich, dass diese 
Polymorphismen einen Effekt auf das Level der Genexpression im Karunkel der 
Mutterschafe haben. 
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9 Appendix 
 
Appendix 1: Codon-amino acid abbreviations 
 
Codon Full Name 
Abbreviation  
(3 Letter) 
Abbreviation  
(1 Letter) 
TTT Phenylalanine Phe F 
TTC Phenylalanine Phe F 
TTA Leucine Leu L 
TTG Leucine Leu L 
TCT Serine Ser S 
TCC Serine Ser S 
TCA Serine Ser S 
TCG Serine Ser S 
TAT Tyrosine Tyr Y 
TAC Tyrosine Tyr Y 
TAA Termination (ochre) Ter X 
TAG Termination (amber) Ter X 
TGT Cysteine Cys C 
TGC Cysteine Cys C 
TGA Termination (opal or umber) Ter X 
TGG Tryptophan Trp W 
CTT Leucine Leu L 
CTC Leucine Leu L 
CTA Leucine Leu L 
CTG Leucine Leu L 
CCT Proline Pro P 
CCC Proline Pro P 
CCA Proline Pro P 
CCG Proline Pro P 
CAT Histidine His H 
CAC Histidine His H 
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Appendix 1: Codon-amino acid abbreviations (continued) 
 
Codon Full Name 
Abbreviation  
(3 Letter) 
Abbreviation  
(1 Letter) 
CAA Glutamine Gln Q 
CAG Glutamine Gln Q 
CGT Arginine Arg R 
CGC Arginine Arg R 
CGA Arginine Arg R 
CGG Arginine Arg R 
ATT Isoleucine Ile I 
ATC Isoleucine Ile I 
ATA Isoleucine Ile I 
ATG Methionine Met M 
ACT Threonine Thr T 
ACC Threonine Thr T 
ACA Threonine Thr T 
ACG Threonine Thr T 
AAT Asparagine Asn N 
AAC Asparagine Asn N 
AAA Lysine Lys K 
AAG Lysine Lys K 
AGT Serine Ser S 
AGC Serine Ser S 
AGA Arginine Arg R 
AGG Arginine Arg R 
GTT Valine Val V 
GTC Valine Val V 
GTA Valine Val V 
GTG Valine Val V 
GCT Alanine Ala A 
GCC Alanine Ala A 
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Appendix 1: Codon-amino acid abbreviations (continued) 
 
Codon Full Name 
Abbreviation  
(3 Letter) 
Abbreviation  
(1 Letter) 
GCA Alanine Ala A 
GCG Alanine Ala A 
GAT Aspartate Asp D 
GAC Aspartate Asp D 
GAA Glutamate Glu E 
GAG Glutamate Glu E 
GGT Glycine Gly G 
GGC Glycine Gly G 
GGA Glycine Gly G 
GGG Glycine Gly G 
n/a Aspartate or Asparagine n/a B 
n/a Glutamate or Glutamine n/a Z 
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